<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="2fb10179-abf5-77e9-e063-6394a90aaf20"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use CITALOPRAM TABLETS safely and effectively. See full prescribing information for CITALOPRAM TABLETS.
 <br/>
      <br/>
CITALOPRAM Tablets, for oral use Initial U.S. Approval: 1998
</title>
   <effectiveTime value="20250306"/>
   <setId root="c9809dfe-939e-4f9d-b6dd-f9808fd9f2b1"/>
   <versionNumber value="11"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="829572556"/>
            <name>REMEDYREPACK INC.</name>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="2fb2597d-6b46-1c8d-e063-6394a90aeaca"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250306"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70518-2228" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Citalopram</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Citalopram</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="69097-824" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="D9C330MD8B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>COPOVIDONE K25-31</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0WZ8WG20P6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (6 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0VUT3PMY82" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (3 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 400</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="40"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="I1E9D14F36" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CITALOPRAM HYDROBROMIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="0DHU5B8D6V" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CITALOPRAM</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="70518-2228-0" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20190713"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="90" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="70518-2228-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20191005"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="70518-2228-2" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20221018"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA077534" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20190713"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="9" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">208;IG</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="BOXED_WARNING">
               <id root="2fb10179-abf6-77e9-e063-6394a90aaf20"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: SUICIDAL THOUGHTS AND BEHAVIORS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short- term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors</content>
                     <content styleCode="bold">
                        <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#_48514375-6f1e-39d4-1a51-aebc9d2633d4">5.1</linkHtml>)].
  
   </content>
                     </content>
                     <content styleCode="bold">Citalopram is not approved for use in pediatric patients</content>
                     <content styleCode="bold">
                        <content styleCode="italics">[see Use in Specific Populations (
   
    <linkHtml href="#PEDIATRIC_USE">8.4</linkHtml>)].
  
   </content>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20250306"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: SUICIDAL THOUGHTS AND BEHAVIORS</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <content styleCode="bold">Increased risk of suicidal thoughts and behavior in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors (
   
      <linkHtml href="#_48514375-6f1e-39d4-1a51-aebc9d2633d4">5.1</linkHtml>).
  
     </content>
                           </item>
                           <item>
                              <content styleCode="bold">Citalopram is not approved for use in pediatric patients (
   
      <linkHtml href="#PEDIATRIC_USE">8.4</linkHtml>).
  
     </content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="L59b35275-70ec-4143-8ba3-58e9ac3e2f31">
               <id root="2fb10179-abf7-77e9-e063-6394a90aaf20"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <text/>
               <effectiveTime value="20250306"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Warnings and Precautions (
 
    <linkHtml href="#_e945bae7-2553-c977-6edc-47c060dc5ae2">5.3</linkHtml>,
 
    <linkHtml href="#_23a1dbcf-5297-d1a2-b890-c290cc6f3b28">5.4</linkHtml>)                                                                                     8/2023

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="INDICATIONS_AND_USAGE">
               <id root="2fb10179-abf8-77e9-e063-6394a90aaf20"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Citalopram is indicated for the treatment of major depressive disorder (MDD) in adults
 
  <content styleCode="italics">[see Clinical Studies (
  
   <linkHtml href="#CLINICAL_STUDIES">14</linkHtml>)]
 
  </content>.

 </paragraph>
               </text>
               <effectiveTime value="20250306"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Citalopram is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder (MDD) in adults (
 
    <content styleCode="italics">
                              <linkHtml href="#INDICATIONS_AND_USAGE">1</linkHtml>
                           </content>).

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="DOSAGE_AND_ADMINISTRATION">
               <id root="2fb10179-abf9-77e9-e063-6394a90aaf20"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250306"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Administer once daily with or without food (
  
     <content styleCode="italics">
                                 <linkHtml href="#DOSAGE_AND_ADMINISTRATION">2</linkHtml>
                              </content>).
 
    </item>
                           <item>Initial dosage is 20 mg once daily; after one week may increase to maximum dosage of 40 mg once daily (
  
     <content styleCode="italics">
                                 <linkHtml href="#_63a598d0-d91b-0e09-4c3d-eadfcf74e6f7">2.1</linkHtml>
                              </content>).
 
    </item>
                           <item>Patients greater than 60 years of age, patients with hepatic impairment, and CYP2C19 poor metabolizers: maximum recommended dosage is 20 mg once daily (
  
     <content styleCode="italics">
                                 <linkHtml href="#_e9a6857d-be6d-fb16-a07f-b6fe3fdf76b3">2.2</linkHtml>
                              </content>).
 
    </item>
                           <item>When discontinuing Citalopram, reduce dosage gradually (
  
     <content styleCode="italics">
                                 <linkHtml href="#_3706b3c7-44ab-41b0-7ca6-20b4330e51be">2.4</linkHtml>,
   
      <linkHtml href="#_015cc08b-88c7-1d83-340a-b8cce4b471cc">5.6</linkHtml>)
  
     </content>.
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_63a598d0-d91b-0e09-4c3d-eadfcf74e6f7">
                     <id root="2fb10179-abfa-77e9-e063-6394a90aaf20"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Recommended Dosage</title>
                     <text>
                        <paragraph>Administer Citalopram once daily, with or without food, at an initial dosage of 20 mg once daily, with an increase to a maximum dosage of 40 mg once daily at an interval of no less than one week.</paragraph>
                        <paragraph/>
                        <paragraph>Dosages above 40 mg once daily are not recommended due to the risk of QT prolongation
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#_c57f8364-ebf6-62b4-b714-306d812a885f">5.2</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="_e9a6857d-be6d-fb16-a07f-b6fe3fdf76b3">
                     <id root="2fb10179-abfb-77e9-e063-6394a90aaf20"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Screen for Bipolar Disorder Prior to Starting Citalopram</title>
                     <text>
                        <paragraph>Prior to initiating treatment with Citalopram or another antidepressant, screen patients for a personal or family history of bipolar disorder, mania, or hypomania
 
  <content styleCode="italics"> [See Warnings and Precautions (
  
   <linkHtml href="#_c6ae9732-6d28-1dac-43b3-d67dc3525a5e">5.5</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="_9db52f15-495c-21b0-069f-45fa2f606310">
                     <id root="2fb10179-abfc-77e9-e063-6394a90aaf20"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Recommended Dosage for Specific Populations</title>
                     <text>
                        <paragraph>The maximum recommended dosage of Citalopram for patients who are greater than 60 years of age, patients with hepatic impairment, and for CYP2C19 poor metabolizers is 20 mg once daily
 
  <content styleCode="italics"> [see Warnings and Precautions (
  
   <linkHtml href="#_c57f8364-ebf6-62b4-b714-306d812a885f">5.2</linkHtml>), Clinical Pharmacology (
  
   <linkHtml href="#PHARMACOKINETICS">12.3</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="_3706b3c7-44ab-41b0-7ca6-20b4330e51be">
                     <id root="2fb10179-abfd-77e9-e063-6394a90aaf20"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Dosage Modifications with Concomitant Use of CYP2C19 Inhibitors</title>
                     <text>
                        <paragraph>The Maximum recommended dosage of Citalopram when used concomitantly with a CYP2C19 inhibitor is 20 mg once daily
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <content styleCode="italics">
                                 <linkHtml href="#_c57f8364-ebf6-62b4-b714-306d812a885f">5.2</linkHtml>), Drug Interactions (
   
    <linkHtml href="#DRUG_INTERACTIONS">7</linkHtml>)
  
   </content>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="_88554978-a46e-11ec-b909-0242ac120002">
                     <id root="2fb10179-abfe-77e9-e063-6394a90aaf20"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Switching Patients to or from a Monoamine Oxidase Inhibitor Antidepressant</title>
                     <text>
                        <paragraph>At least 14 days must elapse between discontinuation of a monoamine oxidase inhibitor (MAOI) antidepressant and initiation of therapy with Citalopram. Conversely, at least 14 days must elapse after stopping Citalopram before starting an MAOI antidepressant 
 
  <content styleCode="italics">[see Contraindications (
  
   <linkHtml href="#CONTRAINDICATIONS">4</linkHtml>) and Warnings and Precautions (
  
   <linkHtml href="#_e945bae7-2553-c977-6edc-47c060dc5ae2">5.3</linkHtml>)].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="_30a82ffe-a470-11ec-b909-0242ac120002">
                     <id root="2fb10179-abff-77e9-e063-6394a90aaf20"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Discontinuing Treatment with Citalopram</title>
                     <text>
                        <paragraph>Adverse reactions may occur upon discontinuation of Citalopram
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#_015cc08b-88c7-1d83-340a-b8cce4b471cc">5.6</linkHtml>)].
 
  </content>Gradually reduce the dosage rather than stopping Citalopram abruptly whenever possible.

 </paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="DOSAGE_FORMS_AND_STRENGTHS">
               <id root="2fb10940-8c9f-86f5-e063-6394a90a505f"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Citalopram tablets, USP are available as:</paragraph>
                  <paragraph/>
                  <list listType="unordered">
                     <item>40 mg: White film coated, round, bi-convex tablets de-bossed with "I" on the left side of bisect and "G" on the right side of bisect on one
   <br/>
	 side and "208" on the other.
  </item>
                  </list>
               </text>
               <effectiveTime value="20250306"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets: 40 mg, scored ( 
    <linkHtml href="#DOSAGE_FORMS_AND_STRENGTHS">3</linkHtml>)
   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="CONTRAINDICATIONS">
               <id root="2fb10179-ac01-77e9-e063-6394a90aaf20"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Citalopram is contraindicated in patients:</paragraph>
                  <list listType="unordered">
                     <item>taking, or within 14 days of stopping, MAOIs (including MAOIs such as linezolid or intravenous methylene blue) because of an increased risk of serotonin syndrome
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#_e945bae7-2553-c977-6edc-47c060dc5ae2">5.3</linkHtml>), Drug Interactions (
   
    <linkHtml href="#DRUG_INTERACTIONS">7</linkHtml>)]
  
   </content>.
 
  </item>
                     <item>taking pimozide because of risk of QT prolongation
  
   <content styleCode="italics">[see Drug Interactions (
   
    <linkHtml href="#DRUG_INTERACTIONS">7</linkHtml>)]
  
   </content>.
 
  </item>
                     <item>with known hypersensitivity to citalopram or any of the inactive ingredients in Citalopram. Reactions have included angioedema and anaphylaxis
  
   <content styleCode="italics">[see Adverse Reactions (
   
    <linkHtml href="#_2476c2d1-41e6-470b-24ff-58dac2ad9ade">6.2</linkHtml>)]
  
   </content>.
 
  </item>
                  </list>
               </text>
               <effectiveTime value="20250306"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Concomitant use of monoamine oxidase inhibitors (MAOIs) or use within 14 days of discontinuing a MAOI. (
  
     <content styleCode="italics">
                                 <linkHtml href="#CONTRAINDICATIONS">4</linkHtml>
                              </content>).
 
    </item>
                           <item>Concomitant use of pimozide. (
  
     <content styleCode="italics">
                                 <linkHtml href="#CONTRAINDICATIONS">4</linkHtml>
                              </content>).
 
    </item>
                           <item>Known hypersensitivity to citalopram or any of the inactive ingredients of Citalopram (
  
     <content styleCode="italics">
                                 <linkHtml href="#CONTRAINDICATIONS">4</linkHtml>
                              </content>).
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="WARNINGS_AND_PRECAUTIONS">
               <id root="2fb10179-ac02-77e9-e063-6394a90aaf20"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250306"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <content styleCode="italics">QT-Prolongation and Torsade de Pointes</content>: Dose-dependent QTc prolongation, Torsade de pointes, ventricular tachycardia, and sudden death have occurred. Avoid use of Citalopram in patients with congenital long QT syndrome, bradycardia, hypokalemia or hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure and patients taking other drugs that prolong the QTc interval. Monitor electrolytes in patients at high risk for hypokalemia or hypomagnesemia. Discontinue Citalopram in patients with persistent QTc measurements &gt; 500 ms (
  
     <linkHtml href="#_c57f8364-ebf6-62b4-b714-306d812a885f">5.2</linkHtml>,
  
     <linkHtml href="#DRUG_INTERACTIONS">7</linkHtml>).
 
    </item>
                           <item>
                              <content styleCode="italics">Serotonin Syndrome:</content>Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. If occurs, discontinue Citalopram and initiate supportive measures (
  
     <linkHtml href="#_e945bae7-2553-c977-6edc-47c060dc5ae2">5.3</linkHtml>).
 
    </item>
                           <item>
                              <content styleCode="italics">Increased Risk of Bleeding:</content>Concomitant use of aspirin, nonsteroidal anti- inflammatory drugs, other antiplatelet drugs, warfarin and other anticoagulants may increase this risk (
  
     <content styleCode="italics">
                                 <linkHtml href="#_23a1dbcf-5297-d1a2-b890-c290cc6f3b28">5.4</linkHtml>
                              </content>).
 
    </item>
                           <item>
                              <content styleCode="italics">Activation of Mania/Hypomania</content>: Screen patients for bipolar disorder (
  
     <content styleCode="italics">
                                 <linkHtml href="#_c6ae9732-6d28-1dac-43b3-d67dc3525a5e">5.5</linkHtml>
                              </content>).
 
    </item>
                           <item>
                              <content styleCode="italics">Seizures:</content>Use with caution in patients with seizure disorder (
  
     <content styleCode="italics">
                                 <linkHtml href="#_1ce9b314-323b-dae2-3a2d-bc1fa3d001b6">5.7</linkHtml>
                              </content>).
 
    </item>
                           <item>
                              <content styleCode="italics">Angle-Closure Glaucoma:</content>Avoid use of Citalopram in patients with untreated anatomically narrow angles (
  
     <content styleCode="italics">
                                 <linkHtml href="#_e7914ce7-a06a-df49-7546-05a7bac9a7e4">5.8</linkHtml>)
  
     </content>.
 
    </item>
                           <item>
                              <content styleCode="italics">Hyponatremia</content>: Can occur in association with syndrome of inappropriate antidiuretic hormone secretion (
  
     <content styleCode="italics">
                                 <linkHtml href="#_13c2b1b9-7f20-b5a5-0c4c-5cc656c9d7c3">5.9</linkHtml>
                              </content>).
 
    </item>
                           <item>
                              <content styleCode="italics">Sexual Dysfunction</content>: Citalopram may cause symptoms of sexual dysfunction. (
  
     <linkHtml href="#_35b1dd25-a390-3c43-365f-a19beaf120c8">5.10</linkHtml>).
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_48514375-6f1e-39d4-1a51-aebc9d2633d4">
                     <id root="2fb10179-ac03-77e9-e063-6394a90aaf20"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Suicidal Thoughts and Behavior in Adolescents and Young Adults</title>
                     <text>
                        <paragraph>In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients, and 4,500 pediatric patients, the incidence of suicidal thoughts and behaviors in antidepressant-treated patients age 24 years and younger was greater than in placebo-treated patients. There was considerable variation in risk of suicidal thoughts and behaviors among drugs, but there was an increased risk identified in young patients for most drugs studied. There were differences in absolute risk of suicidal thoughts and behaviors across the different indications, with the highest incidence in patients with MDD. The drug-placebo differences in the number of cases of suicidal thoughts and behaviors per 1000 patients treated are provided in
 
  <content styleCode="italics">Table 1</content>.

 </paragraph>
                        <table width="100%">
                           <caption>Table 1: Risk Differences of the Number of Patients with Suicidal Thoughts and Behaviors in the Pooled Placebo-Controlled Trials of Antidepressants in Pediatric and Adult Patients</caption>
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Age Range
     
      <footnote ID="t1f1">Citalopram is not approved for use in pediatric patients.</footnote>
                                    </content>
                                 </td>
                                 <td align="center" styleCode="Rrule">
                                    <content styleCode="bold">Drug-Placebo Difference in Number of Patients with Suicidal Thoughts or Behaviors per 1000 Patients Treated</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule"/>
                                 <td align="center" styleCode="Rrule">
                                    <content styleCode="bold">Increases Compared to Placebo</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule">&lt;18 years old</td>
                                 <td align="center" styleCode="Rrule">14 additional patients</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule">18-24 years old</td>
                                 <td align="center" styleCode="Rrule">5 additional patients</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule"/>
                                 <td align="center" styleCode="Rrule">
                                    <content styleCode="bold">Decreases Compared to Placebo</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule">25-64 years old</td>
                                 <td align="center" styleCode="Rrule">1 fewer patient</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Lrule Rrule">≥65 years old</td>
                                 <td align="center" styleCode="Rrule">6 fewer patients</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>It is unknown whether the risk of suicidal thoughts and behaviors in children, adolescents, and young adults extends to longer-term use, i.e., beyond four months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with MDD that antidepressants delay the recurrence of depression and that depression itself is a risk factor for suicidal thoughts and behaviors.</paragraph>
                        <paragraph>Monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy and at times of dosage changes. Counsel family members or caregivers of patients to monitor for changes in behavior and to alert the healthcare provider. Consider changing the therapeutic regimen, including possibly discontinuing Citalopram, in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.</paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="_c57f8364-ebf6-62b4-b714-306d812a885f">
                     <id root="2fb10179-ac04-77e9-e063-6394a90aaf20"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 QT-Prolongation and Torsade de Pointes</title>
                     <text>
                        <paragraph>Citalopram causes dose dependent QTc prolongation an ECG abnormality that has been associated with Torsade de Pointes (TdP), ventricular tachycardia, and sudden death, all of which have been observed in post marketing reports for citalopram
 
  <content styleCode="italics">[see Adverse Reactions
  
   <linkHtml href="#_2476c2d1-41e6-470b-24ff-58dac2ad9ade">6.2</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph>Because of the risk of QTc prolongation at higher citalopram doses, it is recommended that citalopram not be given at doses above 40 mg once daily
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#_63a598d0-d91b-0e09-4c3d-eadfcf74e6f7">2.1</linkHtml>), Clinical Pharmacology (
  
   <linkHtml href="#PHARMACODYNAMICS">12.2</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph>Citalopram should be avoided in patients with congenital long QT syndrome, bradycardia, hypokalemia or hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure unless the benefits outweigh the risks for a particular patient. Citalopram should also be avoided in patients who are taking other drugs that prolong the QTc interval
 
  <content styleCode="italics">[see Drug Interactions (
  
   <linkHtml href="#DRUG_INTERACTIONS">7</linkHtml>)]
 
  </content>. Such drugs include Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval (e.g., pentamidine, levomethadyl acetate, methadone).

 </paragraph>
                        <paragraph/>
                        <paragraph>The citalopram dose should be limited in certain populations. The maximum dose should be limited to 20 mg once daily in patients who are CYP2C19 poor metabolizers or those patients receiving concomitant cimetidine or another CYP2C19 inhibitor, since higher citalopram exposures would be expected. The maximum dose should also be limited to 20 mg once daily in patients with hepatic impairment and in patients who are greater than 60 years of age because of expected higher exposures
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#_9db52f15-495c-21b0-069f-45fa2f606310">2.3</linkHtml>,
  
   <linkHtml href="#_3706b3c7-44ab-41b0-7ca6-20b4330e51be">2.4</linkHtml>), Drug Interactions (
  
   <linkHtml href="#DRUG_INTERACTIONS">7</linkHtml>), Use in Specific Populations (
  
   <linkHtml href="#GERIATRIC_USE">8.5</linkHtml>), Clinical Pharmacology (
  
   <linkHtml href="#PHARMACOKINETICS">12.3</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph/>
                        <paragraph>Electrolyte and/or ECG monitoring is recommended in certain circumstances. Patients being considered for treatment with Citalopram who are at risk for significant electrolyte disturbances should have baseline serum potassium and magnesium measurements with periodic monitoring. Hypokalemia (and/or hypomagnesemia) may increase the risk of QTc prolongation and arrhythmia and should be corrected prior to initiation of treatment and periodically monitored. ECG monitoring is recommended in patients for whom Citalopram use is not recommended unless the benefits clearly outweigh the risks for a particular patient (see above). These include those patients with the cardiac conditions noted above, and those taking other drugs that may prolong the QTc interval.</paragraph>
                        <paragraph/>
                        <paragraph>Discontinue Citalopram in patients who are found to have persistent QTc measurements &gt;500 ms. If patients taking Citalopram experience symptoms that could indicate the occurrence of cardiac arrhythmias, e.g., dizziness, palpitations, orsyncope, the prescriber should initiate further evaluation, including cardiac monitoring.</paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="_e945bae7-2553-c977-6edc-47c060dc5ae2">
                     <id root="2fb10179-ac05-77e9-e063-6394a90aaf20"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Serotonin Syndrome</title>
                     <text>
                        <paragraph>SSRIs, including Citalopram, can precipitate serotonin syndrome, a potentially life-threatening condition. The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone,  tryptophan, buspirone, amphetamines, and St. John’s Wort) and with drugs that impair metabolism of serotonin, i.e., MAOIs 
 
  <content styleCode="italics">[see Contraindications (
  
   <linkHtml href="#CONTRAINDICATIONS">4</linkHtml>), Drug Interactions (
  
   <linkHtml href="#DRUG_INTERACTIONS">7</linkHtml>)]
 
  </content>. Serotonin syndrome can also occur when these drugs are used alone. Symptoms of serotonin syndrome were noted in 0.1% of MDD patients treated with Citalopram in premarketing  clinical trials.

 </paragraph>
                        <paragraph>Serotonin syndrome signs and symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).</paragraph>
                        <paragraph>The concomitant use of Citalopram with MAOIs is contraindicated. In addition, do not initiate Citalopram in a patient being treated with MAOIs such as linezolid or intravenous methylene blue. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection). If it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking Citalopram, discontinue Citalopram before initiating treatment with the MAOI 
 
  <content styleCode="italics">[see Contraindications (
  
   <linkHtml href="#CONTRAINDICATIONS">4</linkHtml>), Drug Interactions (
  
   <linkHtml href="#DRUG_INTERACTIONS">7</linkHtml>)].
 
  </content>
                        </paragraph>
                        <paragraph>Monitor all patients taking Citalopram for the emergence of serotonin syndrome. Discontinue treatment with Citalopram and any concomitant serotonergic agents immediately if the above symptoms occur and initiate supportive symptomatic treatment. If concomitant use of Citalopram with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms.</paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="_23a1dbcf-5297-d1a2-b890-c290cc6f3b28">
                     <id root="2fb10179-ac06-77e9-e063-6394a90aaf20"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Increased Risk of Bleeding</title>
                     <text>
                        <paragraph>Drugs that interfere with serotonin reuptake inhibition, including Citalopram, increase the risk of bleeding events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDS), other antiplatelet drugs, warfarin, and other anticoagulants may add to this risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding.</paragraph>
                        <paragraph>Based on data from the published observational studies, exposure to SSRIs, particularly in the month before delivery, has been associated with a less than 2-fold increase in the risk of postpartum hemorrhage
 
  <content styleCode="italics">[see Use in Specific Populations (
  
   <linkHtml href="#PREGNANCY">8.1</linkHtml>)].
 
  </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"/>Bleeding events related to drugs that interfere with serotonin reuptake have ranged from ecchymosis, hematoma, epistaxis, and petechiae to life-threatening hemorrhages.

 </paragraph>
                        <paragraph/>
                        <paragraph>Inform patients about the increased risk of bleeding associated with the concomitant use of Citalopram and antiplatelet agents or anticoagulants. For patients taking warfarin, carefully monitor the international normalized ratio
 
  <content styleCode="italics">[see Drug Interactions (
  
   <linkHtml href="#DRUG_INTERACTIONS">7</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="_c6ae9732-6d28-1dac-43b3-d67dc3525a5e">
                     <id root="2fb10179-ac07-77e9-e063-6394a90aaf20"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Activation of Mania or Hypomania</title>
                     <text>
                        <paragraph>In patients with bipolar disorder, treating a depressive episode with Citalopram or another antidepressant may precipitate a mixed/manic episode. In controlled clinical trials, patients with bipolar disorder were excluded; however, symptoms of mania or hypomania were reported in 0.1% of undiagnosed patients treated with Citalopram. Prior to initiating treatment with Citalopram, screen patients for any personal or family history of bipolar disorder, mania, or hypomania
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#_e9a6857d-be6d-fb16-a07f-b6fe3fdf76b3">2.2</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="_015cc08b-88c7-1d83-340a-b8cce4b471cc">
                     <id root="2fb10179-ac08-77e9-e063-6394a90aaf20"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Discontinuation Syndrome</title>
                     <text>
                        <paragraph>Adverse reactions after discontinuation of serotonergic antidepressants, particularly after abrupt discontinuation, include: nausea, sweating, dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesia, such as electric shock sensations), tremor, anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. A gradual reduction in dosage rather than abrupt cessation is recommended whenever possible
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#_30a82ffe-a470-11ec-b909-0242ac120002">2.6</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="_1ce9b314-323b-dae2-3a2d-bc1fa3d001b6">
                     <id root="2fb10179-ac09-77e9-e063-6394a90aaf20"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Seizures</title>
                     <text>
                        <paragraph>Citalopram has not been systematically evaluated in patients with seizure disorders. Patients with a history of seizures were excluded from clinical studies. In clinical trials of Citalopram, seizures occurred in 0.3% of patients treated with Citalopram (a rate of one patient per 98 years of exposure) and 0.5% of patients treated with placebo (a rate of one patient per 50 years of exposure). Citalopram should be prescribed with caution in patients with a seizure disorder.</paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="_e7914ce7-a06a-df49-7546-05a7bac9a7e4">
                     <id root="2fb10179-ac0a-77e9-e063-6394a90aaf20"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Angle-closure Glaucoma</title>
                     <text>
                        <paragraph>The pupillary dilation that occurs following use of many antidepressant drugs, including Citalopram, may trigger an angle closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy. Avoid use of antidepressants, including Citalopram, in patients with untreated anatomically narrow angles.</paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="_13c2b1b9-7f20-b5a5-0c4c-5cc656c9d7c3">
                     <id root="2fb10179-ac0b-77e9-e063-6394a90aaf20"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Hyponatremia</title>
                     <text>
                        <paragraph>Hyponatremia may occur as a result of treatment with SSRIs, including Citalopram. Cases of serum sodium lower than 110 mmol/L have been reported. Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which may lead to falls. Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death. In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH).</paragraph>
                        <paragraph>In patients with symptomatic hyponatremia, discontinue Citalopram and institute appropriate medical intervention. Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs
 
  <content styleCode="italics">[see Use in Specific Populations (
  
   <linkHtml href="#GERIATRIC_USE">8.5</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="_35b1dd25-a390-3c43-365f-a19beaf120c8">
                     <id root="2fb10179-ac0c-77e9-e063-6394a90aaf20"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10 Sexual Dysfunction</title>
                     <text>
                        <paragraph>Use of SSRIs, including Citalopram, may cause symptoms of sexual dysfunction [
 
  <content styleCode="italics">see Adverse Reactions (
  
   <linkHtml href="#_503259d3-5d91-f4e4-4c25-a1e77357247f">6.1</linkHtml>)]
 
  </content>. In male patients, SSRI use may result in ejaculatory delay or failure, decreased libido, and erectile dysfunction. In female patients, SSRI use may result in decreased libido and delayed or absent orgasm.

 </paragraph>
                        <paragraph>It is important for prescribers to inquire about sexual function prior to initiation of Citalopram and to inquire specifically about changes in sexual function during treatment, because sexual function may not be spontaneously reported. When evaluating changes in sexual function, obtaining a detailed history (including timing of symptom onset) is important because sexual symptoms may have other causes, including the underlying psychiatric disorder. Discuss potential management strategies to support patients in making informed decisions about treatment.</paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ADVERSE_REACTIONS">
               <id root="2fb10179-ac0d-77e9-e063-6394a90aaf20"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions are discussed in greater detail in other sections of the labeling:</paragraph>
                  <list listType="unordered">
                     <item>Hypersensitivity reactions
  
   <content styleCode="italics">[see Contraindications (
   
    <linkHtml href="#CONTRAINDICATIONS">4</linkHtml>)]
  
   </content>
                     </item>
                     <item>Suicidal thoughts and behaviors in adolescents and young adults
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#_48514375-6f1e-39d4-1a51-aebc9d2633d4">5.1</linkHtml>)]
  
   </content>
                     </item>
                     <item>QT-prolongation and torsade de pointes
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#_c57f8364-ebf6-62b4-b714-306d812a885f">5.2</linkHtml>)]
  
   </content>
                     </item>
                     <item>Serotonin syndrome
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#_e945bae7-2553-c977-6edc-47c060dc5ae2">5.3</linkHtml>)]
  
   </content>
                     </item>
                     <item>Increased risk of bleeding
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#_23a1dbcf-5297-d1a2-b890-c290cc6f3b28">5.4</linkHtml>)]
  
   </content>
                     </item>
                     <item>Activation of mania or hypomania
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#_c6ae9732-6d28-1dac-43b3-d67dc3525a5e">5.5</linkHtml>)]
  
   </content>
                     </item>
                     <item>Discontinuation syndrome
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#_015cc08b-88c7-1d83-340a-b8cce4b471cc">5.6</linkHtml>)]
  
   </content>
                     </item>
                     <item>Seizures
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#_1ce9b314-323b-dae2-3a2d-bc1fa3d001b6">5.7</linkHtml>)]
  
   </content>
                     </item>
                     <item>Angle-closure glaucoma
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#_e7914ce7-a06a-df49-7546-05a7bac9a7e4">5.8</linkHtml>)]
  
   </content>
                     </item>
                     <item>Hyponatremia
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#_13c2b1b9-7f20-b5a5-0c4c-5cc656c9d7c3">5.9</linkHtml>)]
  
   </content>
                     </item>
                     <item>Sexual Dysfunction
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#_35b1dd25-a390-3c43-365f-a19beaf120c8">5.10</linkHtml>)]
  
   </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250306"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reaction (incidence ≥ 5% and twice placebo) is ejaculation disorder (primarily ejaculation delay) (
 
    <content styleCode="italics">
                              <linkHtml href="#_503259d3-5d91-f4e4-4c25-a1e77357247f">6.1</linkHtml>
                           </content>).

   </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Cipla Ltd. at 1-866-604-3268 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_503259d3-5d91-f4e4-4c25-a1e77357247f">
                     <id root="2fb10179-ac0e-77e9-e063-6394a90aaf20"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice.</paragraph>
                        <paragraph>The safety for Citalopram included citalopram exposures in patients and/or healthy subjects from 3 different groups of studies: 429 healthy subjects in clinical pharmacology/pharmacokinetic studies; 4,422 exposures from patients in controlled and uncontrolled clinical trials, corresponding to approximately 1,370 patient-exposure years. There were, in addition, over 19,000 exposures from mostly open-label, European postmarketing studies. The conditions and duration of treatment with Citalopram varied greatly and included (in overlapping categories) open-label and double-blind studies, inpatient and outpatient studies, fixed-dose and dose-titration studies, and short-term and long-term exposure.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Adverse Reactions Associated with Discontinuation of Treatment</content>
                        </paragraph>
                        <paragraph>Among 1,063 patients with MDD who received Citalopram at doses ranging from 10 mg to 80 mg once daily in placebo- controlled trials of up to 6 weeks duration, 16% discontinued treatment due to an adverse reaction, as compared to 8% of 446 patients receiving placebo. The adverse reactions associated with discontinuation (i.e., associated with discontinuation in at least 1% of Citalopram-treated patients at a rate at least twice that of placebo) are shown in 
 
  <content styleCode="italics">Table 2</content>.

 </paragraph>
                        <table width="100%">
                           <caption>Table 2: Adverse Reactions Associated with Discontinuation of Citalopram Treatment in Short-Term, Placebo-Controlled MDD Trials</caption>
                           <tfoot>
                              <tr styleCode="First Last">
                                 <td colspan="3" valign="top">* A patient can report more than one reason for discontinuation and be counted more than once in this table.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">   Body System/Adverse Reaction</content>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Citalopram</content>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <br/>
                                    <content styleCode="bold">Placebo</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"/>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <content styleCode="bold">(N=1,063)</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <content styleCode="bold">(N=446)</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule">
                                    <content styleCode="bold">   General</content>
                                 </td>
                                 <td/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">      Asthenia</td>
                                 <td align="center" styleCode="Lrule Rrule">1</td>
                                 <td align="center" styleCode="Lrule Rrule">&lt;1</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">   Gastrointestinal Disorders</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">      Nausea</td>
                                 <td align="center" styleCode="Lrule Rrule">4</td>
                                 <td align="center" styleCode="Lrule Rrule">0</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">      Dry Mouth</td>
                                 <td align="center" styleCode="Lrule Rrule">1</td>
                                 <td align="center" styleCode="Lrule Rrule">&lt;1</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">      Vomiting</td>
                                 <td align="center" styleCode="Lrule Rrule">1</td>
                                 <td align="center" styleCode="Lrule Rrule">0</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">   Central and Peripheral Nervous System Disorders</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">      Dizziness</td>
                                 <td align="center" styleCode="Lrule Rrule">2</td>
                                 <td align="center" styleCode="Lrule Rrule">&lt;1</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">   Psychiatric Disorders</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">       Insomnia</td>
                                 <td align="center" styleCode="Lrule Rrule">3</td>
                                 <td align="center" styleCode="Lrule Rrule">1</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">      Somnolence</td>
                                 <td align="center" styleCode="Lrule Rrule">2</td>
                                 <td align="center" styleCode="Lrule Rrule">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">      Agitation</td>
                                 <td align="center" styleCode="Lrule Rrule">1</td>
                                 <td align="center" styleCode="Lrule Rrule">&lt;1</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="italics">Table 3 </content>enumerates the incidence of adverse reactions that occurred among 1,063 patients with MDD who received Citalopram at doses ranging from 10 mg to 80 mg once daily in placebo-controlled trials of up to 6 weeks duration.

 </paragraph>
                        <paragraph>The most common adverse reaction that occurred in Citalopram -treated patients with an incidence of 5% or greater and atleast twice the incidence in placebo patients was ejaculation disorder (primarily ejaculatory delay) in male patients (see
 
  <content styleCode="italics">Table 3</content>).

 </paragraph>
                        <table width="100%">
                           <caption>Table 3: Adverse Reactions (≥2% and Greater than Placebo) Among Citalopram -Treated Patients*</caption>
                           <col width="39%"/>
                           <col width="31%"/>
                           <col width="30%"/>
                           <tfoot>
                              <tr styleCode="First Last">
                                 <td colspan="3" valign="top">
                                    <paragraph>    *Adverse reactions reported by at least 2% of patients treated with Citalopram are reported, except for the following adverse reactions which had an incidence on placebo ≥ Citalopram: headache, asthenia, dizziness, constipation, palpitation,vision abnormal, sleep disorder, nervousness, pharyngitis, micturition disorder, back pain.</paragraph>
                                    <paragraph>
                                       <sup>1</sup>Denominator used was for females only (N=638 Citalopram; N=252 placebo). 
      <br/>
                                       <sup>2</sup>Primarily ejaculatory delay. 
      <br/>
                                       <sup>3</sup>Denominator used was for males only (N=425 Citalopram; N=194 placebo).
    
     </paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td rowspan="2" align="left" styleCode="Lrule Rrule" valign="middle">
                                    <paragraph/>
                                    <paragraph>
                                       <content styleCode="bold">   Body System/Adverse Reaction</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Citalopram</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Placebo</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">(N=1,063)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">(N=446)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">   Gastrointestinal Disorders</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <paragraph>   Nausea</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>21</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>14</paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <paragraph>   Diarrhea</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>8</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>5</paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <paragraph>   Dyspepsia</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>5</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>4</paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <paragraph>   Vomiting</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <paragraph>   Abdominal Pain</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Autonomic Nervous System Disorders</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <paragraph>   Dry Mouth</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>20</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>14</paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <paragraph>   Sweating Increased</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>11</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>9</paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Psychiatric Disorders</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <paragraph>   Somnolence</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>18</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>10</paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <paragraph>   Insomnia</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>15</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>14</paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <paragraph>   Anxiety</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <paragraph>   Anorexia</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <paragraph>   Agitation</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <paragraph>   Dysmenorrhea1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <paragraph>   Libido Decreased</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>&lt;1</paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <paragraph>   Yawning</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>&lt;1</paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Central &amp; Peripheral Nervous System Disorders</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <paragraph>   Tremor</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>8</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph> 6</paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Urogenital</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <paragraph>   Ejaculation Disorder
     
      <sup>2,3</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>6</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <paragraph>   Impotence
     
      <sup>3</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>&lt;1</paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Respiratory System Disorders</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <paragraph>   Upper Respiratory Tract Infection</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>5</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>4</paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <paragraph>   Rhinitis</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">5</td>
                                 <td align="center" styleCode="Lrule Rrule">3</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <paragraph>   Sinusitis</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>&lt;1</paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">General</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <paragraph>   Fatigue</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>5</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <paragraph>   Fever</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>&lt;1</paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Musculoskeletal System Disorders</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <paragraph>   Arthralgia</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule Last">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <paragraph>   Myalgia</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Dose Dependent Adverse Reactions</content>
                        </paragraph>
                        <paragraph>The potential relationship between the dosage of Citalopram and the incidence of adverse reactions was examined in a fixed-dose study in patients with MDD receiving placebo or Citalopram 10 mg, 20 mg 40 mg, or 60 mg (1.5 times the maximum recommended dosage). A positive dose response (p&lt;0.05) was revealed for the following adverse reactions: fatigue, impotence, insomnia, increased sweating, somnolence, and yawning.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="underline">Male and Female Sexual Dysfunction with SSRIs</content>
                        </paragraph>
                        <paragraph>Although changes in sexual desire, sexual performance, and sexual satisfaction often occur as manifestations of a psychiatric disorder, they may also be a consequence of SSRI treatment. However, reliable estimates of the incidence and severity of untoward experiences involving sexual desire, performance, and satisfaction are difficult to obtain, in part because patients and healthcare providers may be reluctant to discuss them. Accordingly, estimates of the incidence of untoward sexual experience and performance cited in labeling may underestimate their actual incidence.</paragraph>
                        <paragraph/>
                        <paragraph>Table 4 displays the incidence of sexual adverse reactions reported by at least 2% of male patients taking Citalopram in a pool of placebo-controlled clinical trials in patients with depression.</paragraph>
                        <table width="90%">
                           <caption>Table 4: Adverse Reactions (≥2%) Related to Sexual Dysfunction in Citalopram -Treated Male Patients in Pooled Placebo-Controlled Clinical Trials of MDD</caption>
                           <col width="60%" align="left"/>
                           <col width="20%" align="center"/>
                           <col width="20%" align="center"/>
                           <tbody>
                              <tr valign="middle">
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule"/>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Citalopram</content>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <content styleCode="bold">Placebo</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">   n (males)</content>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">425 (%)</content>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">194 (%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">   Abnormal ejaculation (mostly ejaculatory delay)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">6.1</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">1</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">   Decreased libido</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">3.8</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">&lt;1</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">   Impotence</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">2.8</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">&lt;1</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In female depressed patients receiving Citalopram, the reported incidence of decreased libido and anorgasmia was 1.3% (n=638 females) and 1.1% (n=252 females), respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Weight Changes</content>
                        </paragraph>
                        <paragraph>Patients treated with Citalopram in controlled trials experienced a weight loss of about 0.5 kg compared to no change for placebo patients.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="underline">ECG Changes</content>
                        </paragraph>
                        <paragraph>In a thorough QT study, Citalopram was found to be associated with a dose-dependent increase in the QTc interval.</paragraph>
                        <paragraph>Electrocardiograms from Citalopram (N=802) and placebo (N=241) groups were compared with respect to outliers defined as subjects with QTc changes over 60 msec from baseline or absolute values over 500 msec post-dose, and subjects with heart rate increases to over 100 bpm or decreases to less than 50 bpm with a 25% change from baseline (tachycardic or bradycardic outliers, respectively). In the Citalopram group 1.9% of the patients had a change from baseline in QTcF &gt;60 msec compared to 1.2% of the patients in the placebo group. None of the patients in the placebo group had a post-dose QTcF &gt;500 msec compared to 0.5% of the patients in the Citalopram group. The incidence of tachycardic outliers was 0.5% in the Citalopram group and 0.4% in the placebo group. The incidence of bradycardic outliers was 0.9% in the Citalopram group and 0.4% in the placebo group.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Other Adverse Reactions Observed During the Premarketing Evaluation of Citalopram</content>
                        </paragraph>
                        <paragraph>The following list of adverse reactions does not include reactions that are: 1) included in
 
  <content styleCode="italics">Table 3 </content>or elsewhere in labeling, 2) for which a drug cause was remote, 3) which were so general as to be uninformative, and those occurring in only one patient.

 </paragraph>
                        <paragraph/>
                        <paragraph>Adverse reactions are categorized by body system and listed in order of decreasing frequency according to the following definitions: frequent adverse reactions are those occurring on one or more occasions in at least 1/100 patients; infrequent adverse reactions are those occurring in less than 1/100 patients to 1/1000 patients; rare adverse reactions are those occurring in fewer than 1/1000 patients.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Cardiovascular</content>-
 
  <content styleCode="italics">Frequent:</content>tachycardia, postural hypotension, hypotension.
 
  <content styleCode="italics">Infrequent:</content>hypertension, bradycardia, edema (extremities), angina pectoris, extrasystoles, cardiac failure, flushing, myocardial infarction, cerebrovascular accident, myocardial ischemia.
 
  <content styleCode="italics">Rare:</content>transient ischemic attack, phlebitis, atrial fibrillation, cardiac arrest, bundle branch block.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Central and Peripheral Nervous System Disorders</content>-
 
  <content styleCode="italics">Frequent:</content>paresthesia, migraine.
 
  <content styleCode="italics">Infrequent:</content>hyperkinesia, vertigo, hypertonia, extrapyramidal disorder, leg cramps, involuntary muscle contractions, hypokinesia, neuralgia, dystonia, abnormal gait, hypoesthesia, ataxia.
 
  <content styleCode="italics">Rare:</content>abnormal coordination, hyperesthesia, ptosis, stupor.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Endocrine Disorders</content>-
 
  <content styleCode="italics">Rare:</content>hypothyroidism, goiter, gynecomastia.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal Disorders</content>-
 
  <content styleCode="italics">Frequent:</content>saliva increased, flatulence.
 
  <content styleCode="italics">Infrequent:</content>gastritis, gastroenteritis, stomatitis, eructation, hemorrhoids, dysphagia, teeth grinding, gingivitis, esophagitis.
 
  <content styleCode="italics">Rare:</content>colitis, gastric ulcer, cholecystitis, cholelithiasis, duodenal ulcer, gastroesophageal reflux, glossitis, jaundice, diverticulitis, rectal hemorrhage, hiccups.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">General</content>-
 
  <content styleCode="italics">Infrequent:</content>hot flushes, rigors, alcohol intolerance, syncope, influenza-like symptoms.
 
  <content styleCode="italics">Rare:</content>hay fever.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Hemic and Lymphatic Disorders</content>-
 
  <content styleCode="italics">Infrequent:</content>purpura, anemia, epistaxis, leukocytosis, leucopenia, lymphadenopathy.
 
  <content styleCode="italics">Rare:</content>pulmonary embolism, granulocytopenia, lymphocytosis, lymphopenia, hypochromic anemia, coagulation disorder, gingival bleeding.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolic and Nutritional Disorders</content>-
 
  <content styleCode="italics">Frequent:</content>decreased weight, increased weight.
 
  <content styleCode="italics">Infrequent:</content>increased hepatic enzymes, thirst, dry eyes, increased alkaline phosphatase, abnormal glucose tolerance.
 
  <content styleCode="italics">Rare:</content>bilirubinemia, hypokalemia, obesity, hypoglycemia, hepatitis, dehydration

 </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal System Disorders</content>-
 
  <content styleCode="italics">Infrequent:</content>arthritis, muscle weakness, skeletal pain.
 
  <content styleCode="italics">Rare:</content>bursitis, osteoporosis.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Psychiatric Disorders</content>-
 
  <content styleCode="italics">Frequent:</content>impaired concentration, amnesia, apathy, depression, increased appetite, aggravated depression, suicide attempt, confusion.
 
  <content styleCode="italics">Infrequent:</content>increased libido, aggressive reaction, paroniria, drug dependence, depersonalization, hallucination, euphoria, psychotic depression, delusion, paranoid reaction, emotional lability, panic reaction, psychosis.
 
  <content styleCode="italics">Rare:</content>catatonic reaction, melancholia.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Reproductive Disorders/Female*</content>-
 
  <content styleCode="italics">Frequent:</content>amenorrhea.
 
  <content styleCode="italics">Infrequent:</content>galactorrhea, breast pain, breast enlargement, vaginal hemorrhage. (*% based on female subjects only: 2955)

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Respiratory System Disorders</content>-
 
  <content styleCode="italics">Frequent:</content>coughing.
 
  <content styleCode="italics">Infrequent:</content>bronchitis, dyspnea, pneumonia.
 
  <content styleCode="italics">Rare:</content>asthma, laryngitis, bronchospasm, pneumonitis, sputum increased.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and Appendages Disorders</content>-
 
  <content styleCode="italics">Frequent:</content>rash, pruritus.
 
  <content styleCode="italics">Infrequent:</content>photosensitivity reaction, urticaria, acne, skin discoloration, eczema, alopecia, dermatitis, skin dry, psoriasis.
 
  <content styleCode="italics">Rare:</content>hypertrichosis, decreased sweating, melanosis, keratitis, cellulitis, pruritus ani.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Special Senses</content>-
 
  <content styleCode="italics">Frequent:</content>abnormal accommodation, taste perversion.
 
  <content styleCode="italics">Infrequent:</content>tinnitus, conjunctivitis, eye pain.
 
  <content styleCode="italics">Rare: </content>mydriasis, photophobia, diplopia, abnormal lacrimation, cataract, taste loss.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Urinary System Disorders</content>-
 
  <content styleCode="italics">Frequent:</content>polyuria.
 
  <content styleCode="italics">Infrequent:</content>micturition frequency, urinary incontinence, urinary retention, dysuria.
 
  <content styleCode="italics">Rare:</content>facial edema, hematuria, oliguria, pyelonephritis, renal calculus, renal pain.

 </paragraph>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="_2476c2d1-41e6-470b-24ff-58dac2ad9ade">
                     <id root="2fb10179-ac0f-77e9-e063-6394a90aaf20"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Post marketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during postapproval use of citalopram, the racemate, or escitalopram, the S-enantiomer of citalopram. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Blood and Lymphatic System Disorders</content>: hemolytic anemia, thrombocytopenia, prothrombin decreased.

 </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Cardiac Disorders</content>: torsade de pointes, ventricular arrhythmia, QT prolonged

 </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Endocrine Disorders</content>: hyperprolactinemia

 </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Eye Disorders</content>: angle-closure glaucoma

 </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal Disorders</content>: gastrointestinal hemorrhage, pancreatitis

 </paragraph>
                        <paragraph>
                           <content styleCode="italics"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">General Disorders and Administrative Site Conditions</content>: withdrawal syndrome

 </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Hepatobiliary Disorders</content>: hepatic necrosis

 </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Immune System Disorders</content>: anaphylaxis, allergic reaction

 </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal and Connective Tissue Disorders</content>: rhabdomyolysis

 </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Nervous System Disorders</content>: grand mal convulsion(s), myoclonus, choreoathetosis, dyskinesia, akathisia, nystagmus

 </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Pregnancy, Puerperium and Perinatal Conditions</content>: spontaneous abortion

 </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Psychiatric Disorders</content>: delirium

 </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Renal and Urinary Disorders</content>: acute renal failure

 </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Reproductive System and Breast Disorders</content>: priapism

 </paragraph>
                        <paragraph/>
                        <paragraph styleCode="TableParagraph">
                           <content styleCode="italics">Respiratory, Thoracic and Mediastinal Disorders:</content>anosmia, hyposmia

 </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Skin and Subcutaneous Tissue Disorders:</content>Stevens Johnson Syndrome, epidermal necrolysis, angioedema, erythema multiforme, ecchymosis

 </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Vascular Disorders:</content>thrombosis

 </paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="DRUG_INTERACTIONS">
               <id root="2fb10179-ac10-77e9-e063-6394a90aaf20"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>Table 5 presents clinically important drug interactions with Citalopram.</paragraph>
                  <table width="80%">
                     <caption>Table 5: Clinically Important Drug Interactions with Citalopram</caption>
                     <col width="20%" align="right" valign="middle"/>
                     <col width="80%" align="left" valign="middle"/>
                     <thead>
                        <tr styleCode="First Last">
                           <th colspan="2" align="left" styleCode="Lrule Rrule" valign="top">Monoamine Oxidase Inhibitors (MAOIs)</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr styleCode="Botrule First">
                           <td align="right" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">Clinical Impact    </content>
                           </td>
                           <td align="left" styleCode="Rrule">Concomitant use of SSRIs, including Citalopram, and MAOIs increases the risk of serotonin syndrome.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="right" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">Intervention    </content>
                           </td>
                           <td align="left" styleCode="Rrule">Citalopram is contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue 
    
     <content styleCode="italics">[see Dosage and Administration (
     
      <linkHtml href="#_88554978-a46e-11ec-b909-0242ac120002">2.5</linkHtml>), Contraindications (
     
      <linkHtml href="#CONTRAINDICATIONS">4</linkHtml>), Warnings and Precautions (
     
      <linkHtml href="#_e945bae7-2553-c977-6edc-47c060dc5ae2">5.3</linkHtml>)].
    
     </content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="2" align="left" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">Pimozide</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="right" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">Clinical Impact:    </content>
                           </td>
                           <td align="left" styleCode="Rrule">Concomitant use of Citalopram with pimozide increases plasma concentrations of pimozide, a drug with a narrow therapeutic index, and may increase the risk of QT prolongation and/or ventricular arrhythmias compared to use of Citalopram alone
    
     <content styleCode="italics"> [see Clinical Pharmacology (
     
      <linkHtml href="#PHARMACODYNAMICS">12.2</linkHtml>)].
    
     </content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="right" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">Intervention:    </content>
                           </td>
                           <td align="left" styleCode="Rrule">Citalopram is contraindicated in patients taking pimozide 
    
     <content styleCode="italics">[see Contraindications(
     
      <linkHtml href="#CONTRAINDICATIONS">4</linkHtml>), Warnings and Precautions (
     
      <linkHtml href="#_c57f8364-ebf6-62b4-b714-306d812a885f">5.2</linkHtml>)].
    
     </content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="2" align="left" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">Drugs that Prolong the QTc Interval</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="right" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">Clinical Impact:   </content>
                           </td>
                           <td align="left" styleCode="Rrule">Concomitant use of Citalopram with drugs that prolong QT can cause additional QT prolongation compared to the use of Citalopram alone 
    
     <content styleCode="italics">[see Clinical Pharmacology (
     
      <linkHtml href="#PHARMACODYNAMICS">12.2</linkHtml>)].
    
     </content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="right" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">Intervention:   </content>
                           </td>
                           <td align="left" styleCode="Rrule">Avoid concomitant use of Citalopram with drugs that prolong the QT interval (Citalopram is contraindicated in patients taking pimozide)
    
     <content styleCode="italics">[see Contraindications (
     
      <linkHtml href="#CONTRAINDICATIONS">4</linkHtml>), Warnings and Precautions (
     
      <linkHtml href="#_c57f8364-ebf6-62b4-b714-306d812a885f">5.2</linkHtml>)].
    
     </content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="2" align="left" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">CYP2C19 Inhibitors</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="right" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">Clinical Impact:   </content>
                           </td>
                           <td align="left" styleCode="Rrule">Concomitant use of Citalopram with CYP2C19 inhibitors increases the risk of QT prolongation and/or ventricular arrhythmias compared to the use of Citalopram alone 
    
     <content styleCode="italics">[see Clinical Pharmacology (
     
      <linkHtml href="#PHARMACODYNAMICS">12.2</linkHtml>)].
    
     </content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="right" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">Intervention:   </content>
                           </td>
                           <td align="left" styleCode="Rrule">The maximum recommended dosage of Citalopram is 20 mg daily when used concomitantly with a CYP2C19 inhibitor 
    
     <content styleCode="italics">[see Dosage and Administration (
     
      <linkHtml href="#_3706b3c7-44ab-41b0-7ca6-20b4330e51be">2.4</linkHtml>), Warnings and Precautions (
     
      <linkHtml href="#_c57f8364-ebf6-62b4-b714-306d812a885f">5.2</linkHtml>)].
    
     </content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="2" align="left" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">Other Serotonergic Drugs</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="right" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">Clinical Impact:   </content>
                           </td>
                           <td align="left" styleCode="Rrule">Concomitant use of Citalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. John's Wort) increases the risk of serotonin syndrome.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="right" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">Intervention:   </content>
                           </td>
                           <td align="left" styleCode="Rrule">Monitor patients for signs and symptoms of serotonin syndrome, particularly during Citalopram initiation and dosage increases. If serotonin syndrome occurs, consider discontinuation of Citalopram and/or concomitant serotonergic drugs 
    
     <content styleCode="italics">[see Warning and Precautions (
     
      <linkHtml href="#_e945bae7-2553-c977-6edc-47c060dc5ae2">5.3</linkHtml>)].
    
     </content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="2" align="left" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">Drugs That Interfere With Hemostasis (antiplatelet agents and anticoagulants)</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="right" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">Clinical Impact:   </content>
                           </td>
                           <td align="left" styleCode="Rrule">Concomitant use of Citalopram and an antiplatelet or anticoagulant may potentiate the risk of bleeding.</td>
                        </tr>
                        <tr styleCode="Botrule Last">
                           <td align="right" styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">Intervention:   </content>
                           </td>
                           <td align="left" styleCode="Rrule">Inform patients of the increased risk of bleeding associated with the concomitant use of Citalopram and antiplatelet agents and anticoagulants. For patients taking warfarin, carefully monitor the international normalized ratio 
    
     <content styleCode="italics">[see Warning and Precautions (
     
      <linkHtml href="#_23a1dbcf-5297-d1a2-b890-c290cc6f3b28">5.4</linkHtml>)].
    
     </content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph/>
               </text>
               <effectiveTime value="20250306"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="italics">CYP2C19 Inhibitors</content>: Citalopram 20 mg daily is the maximum recommended dosage for patients taking concomitant CYP2C19 inhibitors (
 
    <content styleCode="italics">
                              <linkHtml href="#_c57f8364-ebf6-62b4-b714-306d812a885f">5.2</linkHtml>,
  
     <linkHtml href="#DRUG_INTERACTIONS">7.1</linkHtml>
                           </content>).

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="USE_IN_SPECIFIC_POPULATIONS">
               <id root="2fb10179-ac11-77e9-e063-6394a90aaf20"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250306"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <content styleCode="italics">Pregnancy:</content>SSRI use, particularly late in pregnancy, may increase the risk for persistent pulmonary hypertension and symptoms of poor adaptation (respiratory distress, temperature instability, feeding difficulties, hypotonia, tremor, irritability) in the neonate (
  
     <content styleCode="italics">
                                 <linkHtml href="#PREGNANCY">8.1</linkHtml>
                              </content>).
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="PREGNANCY">
                     <id root="2fb10179-ac12-77e9-e063-6394a90aaf20"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Exposure Registry</content>
                        </paragraph>
                        <paragraph>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants during pregnancy. Healthcare providers are encouraged to advise patients to register patients by calling the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or visiting online at
 
  <content styleCode="italics">https://womensmentalhealth.org/research/pregnancyregistry/antidepressants.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph styleCode="TableParagraph">Based on data from published observational studies, exposure to SSRIs, particularly in the month before delivery, has been associated with a less than 2-fold increase in the risk of postpartum hemorrhage
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#_23a1dbcf-5297-d1a2-b890-c290cc6f3b28">5.4</linkHtml>) and Clinical Considerations].
 
  </content>
                        </paragraph>
                        <paragraph>Available data from published epidemiologic studies and postmarketing reports with citalopram use in pregnancy have not established an increased risk of major birth defects or miscarriage. Published studies demonstrated that citalopram levels in both cord blood and amniotic fluid are similar to those observed in maternal serum. There are risks of persistent pulmonary hypertension of the newborn (PPHN)
 
  <content styleCode="italics">(see Data)</content>and/or poor neonatal adaptation with exposure to selective serotonin reuptake inhibitors (SSRIs), including Citalopram, during pregnancy
 
  <content styleCode="italics">.</content>There also are risks associated with untreated depression in pregnancy
 
  <content styleCode="italics">(see Clinical Considerations)</content>.

 </paragraph>
                        <paragraph/>
                        <paragraph>In animal reproduction studies, citalopram caused adverse embryo/fetal effects at doses that caused maternal toxicity
 
  <content styleCode="italics">(see Data)</content>.

 </paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in the clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Disease-Associated Maternal and/or Embryo/Fetal Risk</content>
                        </paragraph>
                        <paragraph>Women who discontinue antidepressants during pregnancy are more likely to experience a relapse of major depression than women who continue antidepressants. This finding is from a prospective longitudinal study of 201 pregnant women with a history of major depressive disorder who were euthymic and taking antidepressants at the beginning of pregnancy. Consider the risk of untreated depression when discontinuing or changing treatment with antidepressant medication during pregnancy and postpartum.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Maternal Adverse Reactions</content>
                        </paragraph>
                        <paragraph>Use of Citalopram in the month before delivery may be associated with an increased risk of postpartum hemorrhage
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#_23a1dbcf-5297-d1a2-b890-c290cc6f3b28">5.4</linkHtml>)].
 
  </content>
                        </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Fetal/Neonatal Adverse Reactions</content>
                        </paragraph>
                        <paragraph>Neonates exposed to Citalopram and other SSRIs late in third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability, and constant crying. These findings are consistent with either a direct toxic effect of SSRIs or possibly, a drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with serotonin syndrome
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#_e945bae7-2553-c977-6edc-47c060dc5ae2">5.3</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Human Data</content>
                        </paragraph>
                        <paragraph>Exposure during late pregnancy to SSRIs may have an increased risk for persistent pulmonary hypertension of the newborn (PPHN). PPHN occurs in 1- 2 per 1,000 live births in the general population and is associated with substantial neonatal morbidity and mortality.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Citalopram was administered orally to pregnant rats during the period of organogenesis at doses of 32, 56, and 112 mg/kg/day, which are approximately 8, 14, and 27 times the Maximum Recommended Human Dose (MRHD) of 40 mg, based on mg/m2 body surface area. Citalopram caused maternal toxicity of CNS clinical signs and decreased weight gain at 112 mg/kg/day, which is 27 times the MRHD. At this maternally toxic dose, citalopram decreased embryo/fetal growth and survival and increased fetal abnormalities (including cardiovascular and skeletal defects). The no observed adverse effect level (NOAEL) for maternal and embryofetal toxicity is 56 mg/kg/day, which is approximately 14 times the MRHD.</paragraph>
                        <paragraph>Citalopram was administered orally to pregnant rabbits during the period of organogenesis at doses up to 16 mg/kg/day, which is approximately 8 times the MRHD of 40 mg, based on mg/m2 body surface area. No maternal or embryofetal toxicity was observed. The NOAEL for maternal and embryofetal toxicity is 16 mg/kg/day, which is approximately 8 times the MRHD.</paragraph>
                        <paragraph>Citalopram was administered orally to pregnant rats during late gestation and lactation periods at doses of 4.8, 12.8, and 32 mg/kg/day, which are approximately 1, 3, and 8 times the MRHD of 40 mg, based on mg/m2 body surface area.</paragraph>
                        <paragraph>Citalopram increased offspring mortality during the first 4 days of birth and decreased offspring growth at 32 mg/kg/day, which is approximately 8 times the MRHD. The NOAEL for developmental toxicity is 12.8 mg/kg/day, which is approximately 3 times the MRHD. In a separate study, similar effects on offspring mortality and growth were seen when dams were treated throughout gestation and early lactation at doses ≥ 24 mg/kg/day, which is approximately 6 times the MRHD. A NOAEL was not determined in that study.</paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="LABOR_AND_DELIVERY">
                     <id root="2fb10179-ac13-77e9-e063-6394a90aaf20"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Data from the published literature report the presence of citalopram in human milk at relative infant doses ranging between 0.7 to 9.4% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 0.78 to 4.3. There are reports of breastfed infants exposed to citalopram experiencing irritability, restlessness, excessive somnolence, decreased feeding, and weight loss (see Clinical Considerations). There is no information about effects of citalopram on milk production.</paragraph>
                        <paragraph>The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Citalopram and any potential adverse effects on the breastfed child from Citalopram or from the underlying maternal condition.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>Monitor breastfeeding infants for adverse reactions, such as irritability, restlessness, excessive somnolence, decreased feeding, and weightloss.</paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="PEDIATRIC_USE">
                     <id root="2fb10179-ac14-77e9-e063-6394a90aaf20"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of Citalopram have not been established in pediatric patients. Two placebo-controlled trials in 407 pediatric patients with MDD have been conducted with Citalopram, and the data were not sufficient to support use in pediatric patients.</paragraph>
                        <paragraph>Antidepressants increase the risk of suicidal thoughts and behaviors in pediatric patients
 
  <content styleCode="italics">[see
  
   <linkHtml href="#BOXED_WARNING">Boxed Warning</linkHtml>, Warnings and Precautions (
  
   <linkHtml href="#_48514375-6f1e-39d4-1a51-aebc9d2633d4">5.1</linkHtml>)]
 
  </content>. Decreased appetite and weight loss have been observed in association with the use of SSRIs in pediatric patients.

 </paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="GERIATRIC_USE">
                     <id root="2fb10179-ac15-77e9-e063-6394a90aaf20"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Of 4422 patients in clinical studies of Citalopram, 1357 were 60 and over, 1034 were 65 and over, and 457 were 75 and over. In two pharmacokinetic studies, citalopram AUC was increased by 23% and 30%, respectively, in subjects ≥ 60 years of age as compared to younger subjects, and its half-life was increased by 30% and 50%, respectively
 
  <content styleCode="italics">[see Clinical Pharmacology (
  
   <linkHtml href="#PHARMACOKINETICS">12.3</linkHtml>)].
 
  </content>Therefore, the maximum recommended dosage in patients 60 years of age and older is lower than younger patients
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#_9db52f15-495c-21b0-069f-45fa2f606310">2.3</linkHtml>),Warnings and Precautions (
  
   <linkHtml href="#_c57f8364-ebf6-62b4-b714-306d812a885f">5.2</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph>SSRIs, including Citalopram, have been associated with cases of clinically significant hyponatremia in elderly patients, who may be at greater risk for this adverse reaction
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#_13c2b1b9-7f20-b5a5-0c4c-5cc656c9d7c3">5.9</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="_18814200-a25d-246d-a57c-ffbbb15771e9">
                     <id root="2fb10179-ac16-77e9-e063-6394a90aaf20"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Hepatic Impairment</title>
                     <text>
                        <paragraph>Increased citalopram exposure occurs in patients with hepatic impairment. The maximum recommended dosage of Citalopram is lower in patients with hepatic impairment
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#_9db52f15-495c-21b0-069f-45fa2f606310">2.3</linkHtml>), Clinical Pharmacology (
  
   <linkHtml href="#PHARMACOKINETICS">12.3</linkHtml>)].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="DRUG_ABUSE_AND_DEPENDENCE">
               <id root="2fb10179-ac17-77e9-e063-6394a90aaf20"/>
               <code code="42227-9" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG ABUSE AND DEPENDENCE SECTION"/>
               <title>9 DRUG ABUSE AND DEPENDENCE</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250306"/>
               <component>
                  <section ID="CONTROLLED_SUBSTANCE">
                     <id root="2fb10179-ac18-77e9-e063-6394a90aaf20"/>
                     <code code="34085-1" codeSystem="2.16.840.1.113883.6.1" displayName="CONTROLLED SUBSTANCE SECTION"/>
                     <title>9.1 Controlled Substance</title>
                     <text>
                        <paragraph>Citalopram (citalopram HBr) is not a controlled substance.</paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="ABUSE">
                     <id root="2fb10179-ac19-77e9-e063-6394a90aaf20"/>
                     <code code="34086-9" codeSystem="2.16.840.1.113883.6.1" displayName="ABUSE SECTION"/>
                     <title>9.2 Abuse</title>
                     <text>
                        <paragraph>Animal studies suggest that the abuse liability of Citalopram is low. Citalopram has not been systematically studied in humans for its potential for abuse, tolerance, or physical dependence. The premarketing clinical experience with Citalopram did not reveal any drug-seeking behavior. However, these observations were not systematic and it is not possible to predict, on the basis of this limited experience, the extent to which a CNS-active drug will be misused, diverted, and/or abused once marketed. Consequently, health care providers should carefully evaluate Citalopram patients for history of drug abuse and follow such patients closely, observing them for signs of misuse or abuse (e.g., development of tolerance, incrementations of dose, drug-seeking behavior)</paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="OVERDOSAGE">
               <id root="2fb10179-ac1a-77e9-e063-6394a90aaf20"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>The following have been reported with Citalopram tablet overdosage:</paragraph>
                  <list listType="unordered">
                     <item>Seizures, which may be delayed, and altered mental status including coma.</item>
                     <item>Cardiovascular toxicity, which may be delayed, including QRS and QTc interval prolongation, wide complex tachyarrhythmias, and torsade de pointes. Hypertension most commonly seen, but rarely can see hypotension alone or with co‐ingestants including alcohol.</item>
                     <item>Serotonin syndrome (patients with a multiple drug overdosage with other proserotonergic drugs may have a higher risk).</item>
                  </list>
                  <paragraph>Prolonged cardiac monitoring is recommended in Citalopram overdosage ingestions due to the arrhythmia risk. Gastrointestinal decontamination with activated charcoal should be considered in patients who present early after a Citalopram overdose. Consider contacting a Poison Center (1‐800‐221‐2222) or a medical toxicologist for additional overdosage management recommendations.</paragraph>
               </text>
               <effectiveTime value="20250306"/>
            </section>
         </component>
         <component>
            <section ID="DESCRIPTION">
               <id root="2fb10179-ac1b-77e9-e063-6394a90aaf20"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Citalopram tablet contains citalopram hydrobromide, an orally administered selective serotonin reuptake inhibitor (SSRI) with a chemical structure unrelated to that of other SSRIs or of tricyclic, tetracyclic, or other available antidepressant agents. Citalopram hydrobromide is a racemic bicyclic phthalane derivative designated ((±)-1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile, hydrobromide with the following structural formula:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="La7aa94e6-5ba6-4585-beda-caddea8f498a"/>
                  </paragraph>
                  <paragraph>The molecular formula is C20H22BrFN2O and its molecular weight is 405.35.</paragraph>
                  <paragraph>Citalopram hydrobromide occurs as a fine, white to off-white powder. Citalopram hydrobromide is sparingly soluble in water and soluble in ethanol.</paragraph>
                  <paragraph>Citalopram is available only in tablet dosage form.</paragraph>
                  <paragraph>Citalopram tablets, USP 10 mg are film-coated, round tablets containing citalopram hydrobromide in strengths equivalent to 10 mg citalopram base. Citalopram hydrobromide, USP 20 mg and 40 mg tablets are film-coated, round, scored tablets containing citalopram hydrobromide in strengths equivalent to 20 mg or 40 mg citalopram base. Their strengths reflect their citalopram base equivalent content. The 10 mg, 20 mg and 40 mg strength tablets contain 12.49 mg, 24.98 mg and 49.96 mg of citalopram hydrobromide, respectively. The tablets also contain the following.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Inactive ingredients</content>: copovidone, croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, opadry beige (HPMC 2910/hypromellose 6cp, titanium dioxide, macrogol/Peg400, iron oxide yellow and iron oxide red), opadry pink (HPMC 2910/hypromellose 6cP, titanium dioxide, macrogol/Peg400 and iron oxide red) and opadry white (titanium dioxide, HPMC 2910/hypromellose 3cp, HPMC 2910/ hypromellose 6cp, Macrogol/Peg400 and Polysorbate 80) are used as coloring agents in the beige (10 mg) and pink (20 mg) and white (40 mg) tablets.

 </paragraph>
               </text>
               <effectiveTime value="20250306"/>
               <component>
                  <observationMedia ID="La7aa94e6-5ba6-4585-beda-caddea8f498a">
                     <text>Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="str.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="CLINICAL_PHARMACOLOGY">
               <id root="2fb10179-ac1c-77e9-e063-6394a90aaf20"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <text/>
               <effectiveTime value="20250306"/>
               <component>
                  <section ID="MECHANISM_OF_ACTION">
                     <id root="2fb10179-ac1d-77e9-e063-6394a90aaf20"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>The mechanism of action of citalopram is unclear, but is presumed to be related to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT).</paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="PHARMACODYNAMICS">
                     <id root="2fb10179-ac1e-77e9-e063-6394a90aaf20"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">In vitro</content>and
 
  <content styleCode="italics">in vivo</content>studies in animals suggest that citalopram is a selective serotonin reuptake inhibitor (SSRI) with minimal effects on norepinephrine (NE) and dopamine (DA) neuronal reuptake.

 </paragraph>
                        <paragraph/>
                        <paragraph>Citalopram has no or very low affinity for 5-HT1A, 5-HT2A, dopamine D1 and D2, α1-, α2-, and β-adrenergic, histamine H1,gamma aminobutyric acid (GABA), muscarinic cholinergic, and benzodiazepine receptors.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="underline">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph>Individually corrected QTc (QTcNi) interval was evaluated in a randomized, placebo and active (moxifloxacin 400 mg) controlled cross-over, escalating multiple-dose study in 119 healthy subjects. The maximum mean (upper bound of the 95% one-sided confidence interval) difference from placebo were 8.5 (10.8) and 18.5 (21.0) msec for 20 mg and 60 mg (1.5 times the maxium recommended dosage) citalopram, respectively. Based on the established exposure-response relationship, the predicted QTcNi change from placebo (upper bound of the 95% one-sided confidence interval) under the C
 
  <sub>max</sub>for the dose of 40 mg is 12.6 (14.3) msec 
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#_c57f8364-ebf6-62b4-b714-306d812a885f">5.2</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="PHARMACOKINETICS">
                     <id root="2fb10179-ac1f-77e9-e063-6394a90aaf20"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>The single- and multiple-dose pharmacokinetics of citalopram are linear and dose-proportional in a dose range of 10 to 40 mg/day. Biotransformation of citalopram is mainly hepatic, with a mean terminal half-life of about 35 hours. With once daily dosing, steady state plasma concentrations are achieved within approximately one week. At steady state, the extent of accumulation of citalopram in plasma, based on the half-life, is expected to be 2.5 times the plasma concentrations observed after a single dose.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>Following a single oral dose (40 mg tablet) of citalopram, peak blood levels occur at about 4 hours. The absolute bioavailability of citalopram was about 80% relative to an intravenous dose, and absorption is not affected by food.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph/>
                        <paragraph>The volume of distribution of citalopram is about 12 L/kg and the binding of citalopram (CT), demethylcitalopram (DCT) and didemethylcitalopram (DDCT) to human plasma proteins is about 80%.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>Citalopram is metabolized to demethylcitalopram (DCT), didemethylcitalopram (DDCT), citalopram-N-oxide, and a deaminated propionic acid derivative. In humans, unchanged citalopram is the predominant compound in plasma. At steady state, the concentrations of citalopram's metabolites, DCT and DDCT, in plasma are approximately one-half and one-tenth, respectively, that of the parent drug.
 
  <content styleCode="italics">In vitro</content>studies show that citalopram is at least 8 times more potent than its metabolites in the inhibition of serotonin reuptake, suggesting that the metabolites evaluated do not likely contribute significantly to the antidepressant actions of citalopram.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">In vitro</content>studies using human liver microsomes indicated that CYP3A4 and CYP2C19 are the primary isozymes involved in the N-demethylation of citalopram.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>Following intravenous administrations of citalopram, the fraction of drug recovered in the urine as citalopram and DCT was about 10% and 5%, respectively. The systemic clearance of citalopram was 330 mL/min, with approximately 20% of that due to renal clearance.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Geriatric Patients</content>
                        </paragraph>
                        <paragraph>Citalopram pharmacokinetics in subjects ≥ 60 years of age were compared to younger subjects in two normal volunteer studies. In a single-dose study, citalopram AUC and half-life were increased in the subjects ≥ 60 years old by 30% and 50%, respectively, whereas in a multiple-dose study they were increased by 23% and 30%, respectively
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#_9db52f15-495c-21b0-069f-45fa2f606310">2.3</linkHtml>), Warnings and Precautions (
  
   <linkHtml href="#_c57f8364-ebf6-62b4-b714-306d812a885f">5.2</linkHtml>), Use in Specific Populations (
  
   <linkHtml href="#GERIATRIC_USE">8.5</linkHtml>)].
 
  </content>
                        </paragraph>
                        <paragraph/>
                        <paragraph>Male and Female Patients</paragraph>
                        <paragraph>In three pharmacokinetic studies (total N=32), citalopram AUC in women was one and a half to two times that in men. This difference was not observed in five other pharmacokinetic studies (total N=114). In clinical studies, no differences in steady state serum citalopram levels were seen between men (N=237) and women (N=388). There were no gender differences in the pharmacokinetics of DCT and DDCT.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Patients with Hepatic Impairment</content>
                        </paragraph>
                        <paragraph>Citalopram oral clearance was reduced by 37% and half-life was doubled in patients with reduced hepatic function compared to normal subjects
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#_9db52f15-495c-21b0-069f-45fa2f606310">2.3</linkHtml>), Warnings and Precautions (
  
   <linkHtml href="#_c57f8364-ebf6-62b4-b714-306d812a885f">5.2</linkHtml>), Use in Specific Populations (
  
   <linkHtml href="#_18814200-a25d-246d-a57c-ffbbb15771e9">8.6</linkHtml>)].
 
  </content>
                        </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Patients with Renal Impairment</content>
                        </paragraph>
                        <paragraph>In patients with mild to moderate renal impairment, oral clearance of citalopram was reduced by 17% compared to normal subjects. No adjustment of dosage for such patients is recommended. No information is available about the pharmacokinetics of citalopram in patients with severe renal impairment (creatinine clearance &lt; 20 mL/min).</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">CYP2C19 poor metabolizers</content>
                        </paragraph>
                        <paragraph>In CYP2C19 poor metabolizers, citalopram steady state C
 
  <sub>max</sub>and AUC was increased by 68% and 107%, respectively
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#_9db52f15-495c-21b0-069f-45fa2f606310">2.3</linkHtml>),Warnings and Precautions (
  
   <linkHtml href="#_c57f8364-ebf6-62b4-b714-306d812a885f">5.2</linkHtml>)].
 
  </content>
                        </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">CYP2D6 poor metabolizers</content>
                        </paragraph>
                        <paragraph>Citalopram steady state levels were not significantly different in poor metabolizers and extensive metabolizers of CYP2D6.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">In vitro</content>enzyme inhibition data did not reveal an inhibitory effect of citalopram on CYP3A4, -2C9, or -2E1, but did suggest that it is a weak inhibitor of CYP1A2, -2D6, and -2C19. Citalopram would be expected to have little inhibitory effect on
 
  <content styleCode="italics">in vivo</content>metabolism mediated by these enzymes. However,
 
  <content styleCode="italics">in vivo</content>data to address this question are limited

 </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">CYP3A4 and CYP2C19 Inhibitors</content>
                        </paragraph>
                        <paragraph>Since CYP3A4 and CYP2C19 are the primary enzymes involved in the metabolism of citalopram, it is expected that potent inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, and macrolide antibiotics) and inhibitors of CYP2C19 (e.g., omeprazole, cimetidine) might decrease the clearance of citalopram. However, coadministration of citalopram and the potent CYP3A4 inhibitor ketoconazole did not significantly affect the pharmacokinetics of citalopram. 20 mg/day is the maximum recommended citalopram dose in patients taking concomitant cimetidine or another CYP2C19 inhibitor, because of the risk of QT prolongation
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#_e9a6857d-be6d-fb16-a07f-b6fe3fdf76b3">2.2</linkHtml>), Warnings and Precautions (
  
   <linkHtml href="#_c57f8364-ebf6-62b4-b714-306d812a885f">5.2</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph/>
                        <paragraph>Cimetidine</paragraph>
                        <paragraph>In subjects who had received 21 days of 40 mg/day Citalopram, combined administration of 400 mg twice a day cimetidine for 8 days resulted in an increase in citalopram AUC and C
 
  <sub>max</sub>of 43% and 39%, respectively
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#CONTRAINDICATIONS">4</linkHtml>), Warnings and Precautions (
  
   <linkHtml href="#_c57f8364-ebf6-62b4-b714-306d812a885f">5.2</linkHtml>), Drug Interactions (
  
   <linkHtml href="#DRUG_INTERACTIONS">7</linkHtml>)].
 
  </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">CYP2D6 Inhibitors</content>
                        </paragraph>
                        <paragraph>Coadministration of a drug that inhibits CYP2D6 with citalopram is unlikely to have clinically significant effects on citalopram metabolism, based on the study results in CYP2D6 poor metabolizers.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Digoxin</content>
                        </paragraph>
                        <paragraph>In subjects who had received 21 days of 40 mg/day Citalopram, combined administration of Citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Lithium</content>
                        </paragraph>
                        <paragraph>Coadministration of Citalopram (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Pimozide</content>
                        </paragraph>
                        <paragraph>In a controlled study, a single dose of pimozide 2 mg co-administered with citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.</paragraph>
                        <paragraph>Citalopram did not alter the mean AUC or C
 
  <sub>max</sub>of pimozide. The mechanism of this pharmacodynamic interaction is not known
 
  <content styleCode="italics">[see Contraindications (
  
   <linkHtml href="#CONTRAINDICATIONS">4</linkHtml>), Warnings and Precautions (
  
   <linkHtml href="#_c57f8364-ebf6-62b4-b714-306d812a885f">5.2</linkHtml>)].
 
  </content>
                        </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Theophylline</content>
                        </paragraph>
                        <paragraph>Combined administration of Citalopram (40 mg/day for 21 days) and the CYP1A2 substrate theophylline (single dose of 300 mg) did not affect the pharmacokinetics of theophylline. The effect of theophylline on the pharmacokinetics of citalopram was not evaluated.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Warfarin</content>
                        </paragraph>
                        <paragraph>Administration of 40 mg/day Citalopram for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate. Prothrombin time was increased by 5%, the clinical significance of which is unknown.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Carbamazepine</content>
                        </paragraph>
                        <paragraph>Combined administration of Citalopram (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate. Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of citalopram should be considered if the two drugs are co administered.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Triazolam</content>
                        </paragraph>
                        <paragraph>Combined administration of Citalopram (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or triazolam.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Ketoconazole</content>
                        </paragraph>
                        <paragraph>Combined administration of Citalopram (40 mg) and ketoconazole (200 mg) decreased the C
 
  <sub>max</sub>and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.

 </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Metoprolol</content>
                        </paragraph>
                        <paragraph>Administration of 40 mg/day Citalopram for 22 days resulted in a two-fold increase in the plasma levels of the beta- adrenergic blocker metoprolol. Increased metoprolol plasma levels have been associated with decreased cardioselectivity. Coadministration of Citalopram and metoprolol had no clinically significant effects on blood pressure or heart rate.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Imipramine and Other Tricyclic Antidepressants (TCAs)</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">In vitro</content>studies suggest that citalopram is a relatively weak inhibitor of CYP2D6. Coadministration of Citalopram (40 mg/day for 10 days) with the TCA imipramine (single dose of 100 mg), a substrate for CYP2D6, did not significantly affect the plasma concentrations of imipramine or citalopram. However, the concentration of the imipramine metabolite desipramine was increased by approximately 50%. The clinical significance of the desipramine change is unknown

 </paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="NONCLINICAL_TOXICOLOGY">
               <id root="2fb10179-ac20-77e9-e063-6394a90aaf20"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <text/>
               <effectiveTime value="20250306"/>
               <component>
                  <section ID="CARCINOGENESIS_AND_MUTAGENESIS_AND_IMPAIRMENT_OF_FERTILITY">
                     <id root="2fb10179-ac21-77e9-e063-6394a90aaf20"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>Citalopram increased the incidence of small intestine carcinoma in rats treated for 24 months at doses of 8 and 24 mg/kg/day in the diet, which are approximately 2 and 6 times the Maximum Recommended Human Dose (MRHD) of 40 mg, respectively, based on mg/m2 body surface area. A no-effect level (NOEL) for this finding was not established.</paragraph>
                        <paragraph/>
                        <paragraph>Citalopram did not increase the incidence of tumors in mice treated for 18 months at doses up 240 mg/kg/day in the diet, which is approximately 30 times the MRDH of 40 mg based on mg/m2 body surface area.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>Citalopram was mutagenic in the in vitro bacterial reverse mutation assay (Ames test) in 2 of 5 bacterial strains (Salmonella TA98 and TA1537) in the absence of metabolic activation. It was clastogenic in the
 
  <content styleCode="italics">in vitro</content>Chinese hamster lung cell assay for chromosomal aberrations in the presence and absence of metabolic activation. Citalopram was not mutagenic in the
 
  <content styleCode="italics">in vitro</content>mammalian forward gene mutation assay (HPRT) in mouse lymphoma cells or in
 
  <content styleCode="italics">in vitro/in vivo</content>unscheduled DNA synthesis (UDS) assay in rat liver. It was not clastogenic in the in vitro chromosomal aberration assay in human lymphocytes or in two
 
  <content styleCode="italics">in vivo</content>mouse micronucleus assays.

 </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>Citalopram was administered orally to female and male rats at doses of 32, 48, and 72 mg/kg/day prior to and throughout mating and continuing to gestation. These doses are approximately 8, 12, and 17 times the MRHD of 40 mg based on mg/m2 body surface area. Mating and fertility were decreased at doses ≥ 32 mg/kg/day, which is approximately 8 times the MRHD. Gestation duration was increased at 48 mg/kg/day, which is approximately 12 times the MRHD</paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="ANIMAL_PHARMACOLOGY_AND_OR_TOXICOLOGY_SECTION">
                     <id root="2fb10179-ac22-77e9-e063-6394a90aaf20"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2 Animal Toxicology and/or Pharmacology</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Retinal Changes in Rats</content>
                        </paragraph>
                        <paragraph>Pathologic changes (degeneration/atrophy) were observed in the retinas of albino rats in the 2-year carcinogenicity study with citalopram. There was an increase in both incidence and severity of retinal pathology in both male and female rats receiving 80 mg/kg/day, which is approximately 19 times the MRHD of 40 mg based on mg/m
 
  <sup>2</sup>body surface area. Similar findings were not present in rats treated for two years at the dose of 24 mg/kg/day, in mice treated for 18 months at doses up to 240 mg/kg/day, or in dogs treated for one year at doses up to 20 mg/kg/day, which are approximately 6, 29, and 17 times the MRHD, respectively, based on mg/m
 
  <sup>2</sup>body surface area.

 </paragraph>
                        <paragraph/>
                        <paragraph>Additional studies to investigate the mechanism for this pathology have not been performed, and the potential significance of this effect in humans has not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="CLINICAL_STUDIES">
               <id root="2fb10179-ac23-77e9-e063-6394a90aaf20"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>The efficacy of Citalopram as a treatment for major depressive disorder was established in two placebo-controlled studies (of 4 to 6 weeks duration) in adult outpatients (ages 18-66) meeting DSM-III or DSM-III-R criteria for major depressive disorder (MDD) (Studies 1 and 2).</paragraph>
                  <paragraph/>
                  <paragraph>Study 1, a 6-week trial in which patients received fixed Citalopram doses of 10 mg, 20 mg, 40 mg, and 60 mg daily, showed that Citalopram 40 daily and 60 mg daily (1.5 times the maximum recommended daily dosage) was effective as measured by the Hamilton Depression Rating Scale (HAMD) total score, the primary efficacy endpoint. The HAMD-17 is a 17-item, clinician-rated scale used to assess severity of depressive symptoms. Scores on the HAMD-17 range from 0 to 52, with higher scores indicating more severe depression. This study showed no clear effect of the 10 mg and 20 mg daily doses, and the 60 mg daily dose was not more effective than the 40 mg daily dose. Due to the risk of QTc prolongation and ventricular arrhythmias, the maximum recommended dosage of Citalopram is 40 mg once daily.</paragraph>
                  <paragraph/>
                  <paragraph>In study 2, a 4-week, placebo-controlled trial in patients with MDD, the initial dose was 20 mg daily, followed by titration to the maximum tolerated dose or a maximum dose of 80 mg daily (2 times the maximum recommended daily dosage).</paragraph>
                  <paragraph>Patients treated with Citalopram showed statistically significantly greater improvement than placebo patients on the HAMD total score, the primary efficacy endpoint. In three additional placebo-controlled trials in patients with MDD, the difference in response to treatment between patients receiving Citalopram and patients receiving placebo was not statistically significant.</paragraph>
                  <paragraph/>
                  <paragraph>In two long-term studies, patients with MDD who had responded to Citalopram during an initial 6 or 8 weeks of acute treatment were randomized to continuation of Citalopram or placebo. In one study, patients received fixed doses of Citalopram 20 mg or 40 mg daily and in the second study, patients received flexible doses of Citalopram 20 mg daily to 60 mg daily (1.5 times the maximum recommended daily dosage). In both studies, patients receiving continued Citalopram treatment experienced statistically significantly lower relapse rates over the subsequent 6 months compared to those receiving placebo. In the fixed-dose study, the decreased rate of depression relapse was similar in patients receiving 20 mg or 40 mg daily of Citalopram. Due to the risk of QTc prolongation and ventricular arrhythmias, the maximum recommended dosage of Citalopram is 40 mg once daily.</paragraph>
                  <paragraph>Analyses of the relationship between treatment outcome and age, gender, and race did not suggest any differential responsiveness on the basis of these patient characteristics.</paragraph>
               </text>
               <effectiveTime value="20250306"/>
            </section>
         </component>
         <component>
            <section ID="_0e9b3f33-dc65-aead-f394-ea46748de65c">
               <id root="2fb10179-ac24-77e9-e063-6394a90aaf20"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Citalopram Tablets, USP</paragraph>
                  <paragraph>White, film coated, round, bi-convex tablets debossed with I on the left side of bisect and G on right side of bisect on one side and “208” on the other</paragraph>
                  <paragraph/>
                  <paragraph>NDC: 70518-2228-00</paragraph>
                  <paragraph>NDC: 70518-2228-01</paragraph>
                  <paragraph>NDC: 70518-2228-02</paragraph>
                  <paragraph>PACKAGING: 30 in 1 BLISTER PACK</paragraph>
                  <paragraph>PACKAGING: 90 in 1 BOTTLE PLASTIC</paragraph>
                  <paragraph>PACKAGING: 30 in 1 BOTTLE PLASTIC</paragraph>
                  <paragraph/>
                  <paragraph>Storage and Handling</paragraph>
                  <paragraph>Citalopram tablets should be stored at 20-25°C (68 to 77°F); excursions permitted between 15 and 30°C (59-86°F) [see USP Controlled Room Temperature].</paragraph>
                  <paragraph/>
                  <paragraph>Repackaged and Distributed By:</paragraph>
                  <paragraph>Remedy Repack, Inc.</paragraph>
                  <paragraph>625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762</paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20250306"/>
            </section>
         </component>
         <component>
            <section ID="INFORMATION_FOR_PATIENTS">
               <id root="2fb10179-ac25-77e9-e063-6394a90aaf20"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Medication Guide). '</paragraph>
                  <paragraph>
                     <content styleCode="underline">Suicidal Thoughts and Behaviors</content>
                  </paragraph>
                  <paragraph>Advise patients and caregivers to look for the emergence of suicidality, especially early during treatment and when the dosage is adjusted up or down and instruct them to report such symptoms to the healthcare provider.
 
  <content styleCode="italics">[see Boxed Warning, Warnings and Precautions (
  
   <linkHtml href="#_48514375-6f1e-39d4-1a51-aebc9d2633d4">5.1</linkHtml>)].
 
  </content>
                  </paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="underline">QT Prolongation and Torsade de Pointes</content>
                  </paragraph>
                  <paragraph>Advise patients to consult their health care provider immediately if they feel faint, lose consciousness, or have heart palpitations. Instruct patients to inform their health care provider that they are taking Citalopram before taking any new medications
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#_c57f8364-ebf6-62b4-b714-306d812a885f">5.2</linkHtml>), Drug Interactions (
  
   <linkHtml href="#DRUG_INTERACTIONS">7</linkHtml>)].
 
  </content>
                  </paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="underline">Serotonin Syndrome</content>
                  </paragraph>
                  <paragraph>Caution patients about the the risk of serotonin syndrome, particularly with the concomitant use of Citalopram with other serotonergic drugs including triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, St. John’s Wort, and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid). Instruct patients to contact their health care provider or report to the emergency room if they experience signs or symptoms of serotonin syndrome
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#_e945bae7-2553-c977-6edc-47c060dc5ae2">5.3</linkHtml>), Drug Interactions (
  
   <linkHtml href="#DRUG_INTERACTIONS">7</linkHtml>)].
 
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Increased Risk of Bleeding</content>
                  </paragraph>
                  <paragraph>Inform patients about the concomitant use of Citalopram with aspirin, NSAIDs, other antiplatelet drugs,warfarin, or other anticoagulants because the combined use has been associated with an increased risk of bleeding. Advise patients to inform their health care providers if they are taking or planning to take any prescription or over-the counter medications that increase the risk of bleeding
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#_23a1dbcf-5297-d1a2-b890-c290cc6f3b28">5.4</linkHtml>)].
 
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Activation of Mania or Hypomania</content>
                  </paragraph>
                  <paragraph>Advise patients and their caregivers to observe for signs of activation of mania/hypomania and instruct them to report such symptoms to the healthcare provider
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#_c6ae9732-6d28-1dac-43b3-d67dc3525a5e">5.5</linkHtml>)]
 
  </content>.

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Discontinuation Syndrome</content>
                  </paragraph>
                  <paragraph>Advise patients not to abruptly discontinue Citalopram and to discuss any tapering regimen with their healthcare provider. Inform patients that adverse reactions can occur when Citalopram is discontinued 
 
  <content styleCode="italics">[See Warnings and Precautions (
  
   <linkHtml href="#_015cc08b-88c7-1d83-340a-b8cce4b471cc">5.6</linkHtml>)].
 
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Sexual Dysfunction</content>
                  </paragraph>
                  <paragraph>Advise patients that use of Citalopram may cause symptoms of sexual dysfunction in both male and female patients. Inform patients that they should discuss any changes in sexual function and potential management strategies with their healthcare provider
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#_35b1dd25-a390-3c43-365f-a19beaf120c8">5.10</linkHtml>)].
 
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Pregnancy</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Advise patients to notify their healthcare provider if they become pregnant or intend to become pregnant during treatment with Citalopram
  
   <content styleCode="italics">[see Use in Specific Populations (
   
    <linkHtml href="#PREGNANCY">8.1</linkHtml>)].
  
   </content>
                     </item>
                     <item>Advise patients that Citalopram use late in pregnancy may lead to an increased risk for neonatal complications requiring prolonged hospitalization, respiratory support, tube feeding, and/or persistent pulmonary hypertension of the newborn (PPHN)
  
   <content styleCode="italics">[see Use in Specific Populations (
   
    <linkHtml href="#PREGNANCY">8.1</linkHtml>)].
  
   </content>
                     </item>
                     <item>Advise women that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to citalopram during pregnancy
  
   <content styleCode="italics">[see Use in Specific Populations (
   
    <linkHtml href="#PREGNANCY">8.1</linkHtml>)].
  
   </content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Lactation</content>
                  </paragraph>
                  <paragraph>Advise breastfeeding women to monitor infants for excess sedation, restlessness, agitation, poor feeding and poor weight gain and to seek medical care if they notice these signs
 
  <content styleCode="italics">[see Use in Specific Populations (
  
   <linkHtml href="#LABOR_AND_DELIVERY">8.2</linkHtml>)]
 
  </content>.

 </paragraph>
                  <paragraph/>
                  <paragraph>Repackaged By / Distributed By: RemedyRepack Inc.</paragraph>
                  <paragraph>625 Kolter Drive, Indiana, PA 15701</paragraph>
                  <paragraph>(724) 465-8762</paragraph>
               </text>
               <effectiveTime value="20250306"/>
            </section>
         </component>
         <component>
            <section ID="_8e8b4b2e-bd93-793f-c177-6db0fc6b26f4">
               <id root="2fb10179-ac26-77e9-e063-6394a90aaf20"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title/>
               <text>
                  <paragraph>Revised:08/2024</paragraph>
               </text>
               <effectiveTime value="20250306"/>
            </section>
         </component>
         <component>
            <section ID="MEDGUIDE">
               <id root="2fb2591b-aa91-f2d5-e063-6294a90a149c"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <table>
                     <colgroup>
                        <col align="left" width="50.000%"/>
                        <col align="left" width="25.000%"/>
                        <col align="left" width="25.000%"/>
                     </colgroup>
                     <tbody>
                        <tr>
                           <td align="center" colspan="3" styleCode="Botrule Lrule Rrule Toprule" valign="top">
                              <paragraph>
                                 <content styleCode="bold">MEDICATION GUIDE</content>
                                 <br/>
                                 <content styleCode="bold">Citalopram Tablets,USP</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">(sih-TAL-oh-pram)</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" colspan="3" styleCode="Lrule Rrule" valign="top">
                              <paragraph>
                                 <content styleCode="bold">What is the most important information I should know about Citalopram?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Citalopram may cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Increased risk of suicidal thoughts and actions.</content> Citalopram and other antidepressant medicines may increase suicidal thoughts and actions in some children, adolescents, and young adults 
       <content styleCode="bold">especially within the first few months of treatment or when the dose is changed. Citalopram is not for use in children.</content>
                                    <list listType="unordered" styleCode="Circle">
                                       <item>Depression and other mental illnesses are the most important causes of suicidal thoughts and actions.</item>
                                    </list>
                                 </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Circle">
                                 <item>Pay close attention to any changes, especially sudden changes in mood, behavior, thoughts, or feelings, or if you develop suicidal thoughts or actions. This is very important when an antidepressant medicine is started or when the dose is changed.</item>
                                 <item>Call your healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings.</item>
                                 <item>Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you have concerns about symptoms.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Call your healthcare provider or get emergency medical help right away if you or your family member have any of the following symptoms, especially if they are new, worse, or worry you:</content>
                              </paragraph>
                              <paragraph/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Lrule">
                              <list listType="unordered">
                                 <item>thoughts about suicide or dying</item>
                                 <item>new or worse depression</item>
                                 <item>feeling very agitated or restless</item>
                                 <item>trouble sleeping (insomnia)</item>
                                 <item>acting aggressive, being angry, or violent</item>
                                 <item>an extreme increase in activity or talking (mania)</item>
                              </list>
                           </td>
                           <td align="left" colspan="2" styleCode="Rrule">
                              <list listType="unordered">
                                 <item>attempts to commit suicide</item>
                                 <item>new or worse anxiety</item>
                                 <item>acting on dangerous impulses</item>
                                 <item>panic attacks</item>
                                 <item>new or worse irritability</item>
                                 <item>other unusual changes in behavior or mood</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" colspan="3" styleCode="Botrule Lrule Rrule Toprule" valign="top">
                              <paragraph>
                                 <content styleCode="bold">What is Citalopram?</content>
                                 <br/>
			Citalopram is a prescription medicine used to treat a certain type of depression called Major Depressive Disorder (MDD) in adults.
     </paragraph>
                              <paragraph>It is not known if Citalopram is safe and effective for use in children.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" colspan="3" styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>
                                 <content styleCode="bold">Who should not take Citalopram? Do not take Citalopram if you:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>take a Monoamine Oxidase Inhibitor (MAOI)</item>
                                 <item>have stopped taking an MAOI in the last 14 days</item>
                                 <item>are being treated with the antibiotic linezolid or intravenous methylene blue</item>
                                 <item>take pimozide</item>
                                 <item>are allergic to citalopram or any of the ingredients in Citalopram. See the end of this Medication Guide for a complete list of ingredients in Citalopram.</item>
                              </list>
                              <paragraph>Ask your healthcare provider or pharmacist if you are not sure if you take an MAOI, including MAOIs such as linezolid or intravenous methylene blue.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Do not start taking an MAOI for at least 14 days after you stop treatment with Citalopram.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" colspan="3" styleCode="Lrule Rrule" valign="top">
                              <paragraph>
                                 <content styleCode="bold">Before taking Citalopram, tell your healthcare provider about all your medical conditions, including if you:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have or have a family history of suicide, depression, bipolar disorder, mania or hypomania</item>
                                 <item>have an abnormal heart rhythm called QT prolongation</item>
                                 <item>have or had heart problems, including a heart attack, heart failure, abnormal heart rhythm, or long QT syndrome</item>
                                 <item>have low potassium, magnesium, or sodium levels in your blood</item>
                                 <item>have or had bleeding problems</item>
                                 <item>have or had seizures (convulsions)</item>
                                 <item>have high pressure in the eye (glaucoma)</item>
                                 <item>have or had kidney or liver problems</item>
                                 <item>are pregnant or plan to become pregnant. Citalopram may harm your unborn baby. Taking Citalopram late in pregnancy may lead to an increased risk of certain problems in your newborn. Talk to your healthcare provider about the risks and benefits of treating depression during pregnancy.
				
       <list listType="unordered" styleCode="Circle">
                                       <item>Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Citalopram.</item>
                                       <item>There is a pregnancy registry for females who are exposed to Citalopram during pregnancy. The purpose of the registry is to collect information about the health of females exposed to Citalopram and their baby. If you become pregnant during treatment with Citalopram, talk to your healthcare provider about registering with the National Pregnancy Registry for Antidepressants. You can register by calling 1-844-405-6185 or visiting online at https:// womensmentalhealth.org/research/pregnancyregistry/antidepressants.</item>
                                    </list>
                                 </item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if Citalopram passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with Citalopram.
				
       <list listType="unordered" styleCode="Circle">
                                       <item>If you breastfeed during treatment with Citalopram, call your healthcare provider right away if your baby develops sleepiness or fussiness, or is not feeding or gaining weight well.</item>
                                    </list>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" colspan="3" styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>
                                 <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements.
      <br/>
			Citalopram and other medicines may affect each other causing possible serious side effects. Citalopram may affect the way other medicines work and other medicines may affect the way Citalopram works.
      <br/>
                                 <content styleCode="bold">Especially tell your healthcare provider if you take:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>medicines used to treat migraine headaches known as triptans</item>
                                 <item>tricyclic antidepressants</item>
                                 <item>lithium</item>
                                 <item>tramadol, fentanyl, meperidine, methadone, or other opioids</item>
                                 <item>tryptophan</item>
                                 <item>buspirone</item>
                                 <item>amphetamines</item>
                                 <item>St. Johns Wort</item>
                                 <item>medicines that can affect blood clotting such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs) and warfarin</item>
                                 <item>diuretics</item>
                                 <item>methadone</item>
                                 <item>gatifloxacin or moxifloxacin</item>
                                 <item>medicines used to control your heart rate or rhythm (antiarrhythmics)</item>
                                 <item>medicines used to treat mood, anxiety, psychotic or thought disorders, including selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs)</item>
                              </list>
                              <paragraph>Ask your healthcare provider if you are not sure if you are taking any of these medicines. Your healthcare provider can tell you if it is safe to take Citalopram with your other medicines.</paragraph>
                              <paragraph>Do not start or stop any other medicines during treatment with Citalopram without talking to your healthcare provider first. Stopping Citalopram suddenly may cause you to have serious side effects. See, 
      <content styleCode="bold">What are the possible side effects of Citalopram?</content>
                              </paragraph>
                              <paragraph>Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" colspan="3" styleCode="Lrule Rrule" valign="top">
                              <paragraph>
                                 <content styleCode="bold">How should I take Citalopram?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Take Citalopram exactly as your healthcare provider tells you to take it. Do not change your dose or stop taking Citalopram without first talking to your healthcare provider.</item>
                                 <item>Your healthcare provider may need to change the dose of Citalopram until it is the right dose for you.</item>
                                 <item>Take Citalopram 1 time each day with or without food.</item>
                                 <item>If you take too much Citalopram, call your healthcare provider or poison control center at 1-800-222-1222, or go to the nearest hospital emergency room right away</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" colspan="3" styleCode="Lrule Rrule" valign="top">
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of Citalopram?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Citalopram may cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>See, 
       <content styleCode="bold">What is the most important information I should know about Citalopram?.</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Heart rhythm problems. </content>Citalopram may cause a serious change in your heartbeat (a fast or irregular heartbeat) that may cause death. Tell your healthcare provider right away if you feel faint or pass out, or if you have a change in your heart beat.
      </item>
                                 <item>
                                    <content styleCode="bold">Serotonin syndrome. </content>Taking Citalopram can cause a potentially life-threatening problem called serotonin syndrome. The risk of developing serotonin syndrome is increased when Citalopram is taken with certain other medicines. See, 
       <content styleCode="bold">“Who should not take Citalopram?” Call your healthcare provider or go to the nearest hospital emergency room right away</content> if you have any of the following signs and symptoms of serotonin syndrome:
      </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Lrule" valign="top">
                              <list listType="unordered" styleCode="Circle">
                                 <item>agitation</item>
                                 <item>confusion</item>
                                 <item>fast heart beat</item>
                                 <item>dizziness</item>
                                 <item>flushing</item>
                                 <item>tremors, stiff muscles, or muscle twitching</item>
                                 <item>seizures</item>
                              </list>
                           </td>
                           <td align="left" colspan="2" styleCode="Rrule" valign="top">
                              <list listType="unordered" styleCode="Circle">
                                 <item>seeing or hearing things that are not real(hallucinations)</item>
                                 <item>coma</item>
                                 <item>blood pressure changes</item>
                                 <item>sweating</item>
                                 <item>high body temperature (hyperthermia)</item>
                                 <item>loss of coordination</item>
                                 <item>nausea, vomiting, diarrhea</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" colspan="3" styleCode="Lrule Rrule" valign="top">
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">Increased risk of bleeding.</content> Taking Citalopram with aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), warfarin or blood thinners may add to this risk. Tell your healthcare provider right away about any unusual bleeding or bruising.
      </item>
                                 <item>
                                    <content styleCode="bold">Manic episodes.</content> Manic episodes may happen in people with bipolar disorder who take Citalopram Tablets.
      </item>
                              </list>
                              <paragraph>Symptoms may include:</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Lrule" valign="top">
                              <list listType="unordered" styleCode="Circle">
                                 <item>greatly increased energy</item>
                                 <item>racing thoughts</item>
                                 <item>unusually grand ideas</item>
                                 <item>talking more or faster than usual</item>
                              </list>
                           </td>
                           <td align="left" colspan="2" styleCode="Rrule" valign="top">
                              <list listType="unordered" styleCode="Circle">
                                 <item>severe trouble sleeping</item>
                                 <item>reckless behavior</item>
                                 <item>excessive happiness or irritability</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" colspan="3" styleCode="Lrule Rrule" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Discontinuation syndrome.</content> Suddenly stopping Citalopram may cause you to have serious side effects. Your healthcare provider may want to decrease your dose slowly. Symptoms may include:
      </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Lrule" valign="top">
                              <list listType="unordered" styleCode="Circle">
                                 <item>nausea</item>
                                 <item>changes in your mood</item>
                                 <item>irritability and agitation</item>
                                 <item>dizziness</item>
                                 <item>electric shock sensation (paresthesia)</item>
                                 <item>anxiety</item>
                                 <item>confusion</item>
                              </list>
                           </td>
                           <td align="left" colspan="2" styleCode="Rrule" valign="top">
                              <list listType="unordered" styleCode="Circle">
                                 <item>sweating</item>
                                 <item>headache</item>
                                 <item>tiredness</item>
                                 <item>problems sleeping</item>
                                 <item>hypomania</item>
                                 <item>ringing in your ears (tinnitus)</item>
                                 <item>seizures</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" colspan="3" styleCode="Lrule Rrule" valign="top">
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">Seizures (convulsions).</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Eye problems (angle-closure glaucoma). </content>Many antidepressant medicines, including Citalopram, may cause a certain type of eye problem called angle-closure glaucoma. Call your healthcare provider if you have changes in your vision or eye pain.
      </item>
                                 <item>
                                    <content styleCode="bold">Low sodium levels in your blood (hyponatremia).</content> Low sodium levels in your blood may be serious and may cause death. Elderly people may be at greater risk for this. Tell your healthcare provider right away if you develop any signs or symptoms of low sodium levels in your blood during treatment with Citalopram. Signs and symptoms of low sodium levels in your blood may include:
      </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" scope="col" styleCode="Lrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>headache</item>
                                 <item>memory changes</item>
                                 <item>weakness and unsteadiness on your feet which can lead to falls</item>
                              </list>
                           </td>
                           <td align="left" colspan="2" scope="col" styleCode="Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>difficulty concentrating</item>
                                 <item>confusion</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" colspan="3" scope="col" styleCode="Lrule Rrule">
                              <content styleCode="bold">In severe or more sudden cases, signs and symptoms include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" scope="col" styleCode="Lrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>hallucinations (seeing or hearing things that are not real)</item>
                                 <item>seizures</item>
                                 <item>stopping breathing</item>
                              </list>
                           </td>
                           <td align="left" colspan="2" scope="col" styleCode="Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>fainting</item>
                                 <item>coma</item>
                                 <item>death</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" colspan="3" styleCode="Botrule Lrule Rrule" valign="top">
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">Sexual problems (dysfunction). </content>Taking selective serotonin reuptake inhibitors (SSRIs), including Citalopram, may cause sexual problems.
      </item>
                                 <item>
                                    <content styleCode="bold">Symptoms in males may include:</content>
                                 </item>
                              </list>
                              <list listType="unordered" styleCode="Circle">
                                 <item>Delayed ejaculation or inability to have an ejaculation</item>
                                 <item>Decreased sex drive</item>
                                 <item>Problems getting or keeping an erection</item>
                              </list>
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">Symptoms in females may include:</content>
                                 </item>
                              </list>
                              <list listType="unordered" styleCode="Circle">
                                 <item>Decreased sex drive</item>
                                 <item>Delayed orgasm or inability to have an orgasm</item>
                              </list>
                              <paragraph>Talk to your healthcare provider if you develop any changes in your sexual function or if you have any questions or concerns about sexual problems during treatment with citalopram. There may be treatments your healthcare provider can suggest.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">The most common side effect of Citalopram is delayed ejaculation.</content>
                              </paragraph>
                              <paragraph>These are not all the possible side effects of Citalopram.</paragraph>
                              <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                              <paragraph/>
                              <paragraph>
                                 <content styleCode="bold">How should I store Citalopram?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store citalopram tablets at room temperature between 68°F to 77°F (20°C to 25°C).</item>
                                 <item>
                                    <content styleCode="bold">Keep Citalopram and all medicines out of the reach of children.</content>
                                 </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">General information about the safe and effective use of Citalopram</content>
                              </paragraph>
                              <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use citalopram tablets for a condition for which it was not prescribed. Do not give citalopram tablets to other people, even if they have the same symptoms that you have. It may harm them. You may ask your healthcare provider or pharmacist for information about citalopram tablets that is written for healthcare professionals.</paragraph>
                              <paragraph/>
                              <paragraph>For more information about citalopram tablets call Cipla Ltd. at 1-866-604-3268.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in Citalopram Tablets, USP?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Active ingredient:</content> citalopram hydrobromide, USP
     </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Inactive ingredients:</content>Copovidone, Croscarmellose, sodium , lactose monohydrate, magnesium stearate, microcrystalline cellulose, opadry beige (HPMC 2910/hypromellose 6cp,titanium dioxide, macrogol/Peg400, iron oxide yellow and iron oxide red), opadry pink (HPMC 2910/hypromellose 6cP, titaniumdioxide, macrogol/Peg400 and iron oxide red) and opadry white (titanium dioxide, HPMC 2910/hypromellose3cp,HPMC2910/hypromellose 6cp, Macrogol/Peg400 and Polysorbate 80) are used as coating agents in the beige (10 mg), pink (20 mg) and white (40 mg) tablets.
     </paragraph>
                              <paragraph/>
                              <paragraph>
                                 <br/>
			This Medication Guide has been approved by the U.S. Food and Drug Administration.
      <br/>
                                 <br/>
			All brand names listed are the registered trademarks of their respective owners and are not trademarks of Cipla Limited.
     </paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph/>
                  <paragraph>Repackaged By / Distributed By: RemedyRepack Inc.</paragraph>
                  <paragraph>625 Kolter Drive, Indiana, PA 15701</paragraph>
                  <paragraph>(724) 465-8762</paragraph>
               </text>
               <effectiveTime value="20250306"/>
            </section>
         </component>
         <component>
            <section ID="id_link_2fb110c0-31aa-8cfd-e063-6394a90a5068">
               <id root="2fb110c0-31a9-8cfd-e063-6394a90a5068"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>DRUG: Citalopram</paragraph>
                  <paragraph>GENERIC: Citalopram</paragraph>
                  <paragraph>DOSAGE: TABLET</paragraph>
                  <paragraph>ADMINSTRATION: ORAL</paragraph>
                  <paragraph>NDC: 70518-2228-0</paragraph>
                  <paragraph>NDC: 70518-2228-1</paragraph>
                  <paragraph>NDC: 70518-2228-2</paragraph>
                  <paragraph>COLOR: white</paragraph>
                  <paragraph>SHAPE: ROUND</paragraph>
                  <paragraph>SCORE: Two even pieces</paragraph>
                  <paragraph>SIZE: 9 mm</paragraph>
                  <paragraph>IMPRINT: 208;IG</paragraph>
                  <paragraph>PACKAGING: 30 in 1 BLISTER PACK</paragraph>
                  <paragraph>PACKAGING: 90 in 1 BOTTLE PLASTIC</paragraph>
                  <paragraph>PACKAGING: 30 in 1 BOTTLE PLASTIC</paragraph>
                  <paragraph>ACTIVE INGREDIENT(S):</paragraph>
                  <list listType="unordered">
                     <item>CITALOPRAM HYDROBROMIDE 40mg in 1</item>
                  </list>
                  <paragraph>INACTIVE INGREDIENT(S):</paragraph>
                  <list listType="unordered">
                     <item>COPOVIDONE K25-31</item>
                     <item>CROSCARMELLOSE SODIUM</item>
                     <item>LACTOSE MONOHYDRATE</item>
                     <item>MAGNESIUM STEARATE</item>
                     <item>MICROCRYSTALLINE CELLULOSE</item>
                     <item>HYPROMELLOSE 2910 (6 MPA.S)</item>
                     <item>HYPROMELLOSE 2910 (3 MPA.S)</item>
                     <item>TITANIUM DIOXIDE</item>
                     <item>POLYETHYLENE GLYCOL 400</item>
                     <item>POLYSORBATE 80</item>
                  </list>
                  <paragraph>
                     <renderMultiMedia referencedObject="Remedy_Label"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_2fb109c6-bcd2-199f-e063-6294a90aea35"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_2fb11084-8961-894f-e063-6394a90af493"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250306"/>
               <component>
                  <observationMedia ID="Remedy_Label">
                     <text>Remedy_Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Remedy_Label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="img_2fb109c6-bcd2-199f-e063-6294a90aea35">
                     <text>MM2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Citalopram 40mg_70518-2228-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="img_2fb11084-8961-894f-e063-6394a90af493">
                     <text>MM3</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Citalopram 40mg_70518-2228-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>